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Summary 
Vascular calcification is present in atherosclerosis, ageing, chronic kidney diseases and 
diabetes and is strongly associated with an increased morbidity and mortality. Calcification of 
arteries occurs at the tunica intima and the tunica media. Thereby, vascular smooth muscles 
cells (VSMC) transdifferentiate into an osteoblastic phenotype. In contrast to the antiquated 
opinion that calcification of soft tissues is a passive process it is now known that actively 
regulated processes play a major role. Modifiable calcification inhibitors were identified of 
which matrix gla protein (MGP) is regarded as the most potent one being expressed in the 
vascular wall. MGP gets posttranslationally gamma carboxylated at 5 glutamic acid residues, 
which achieve calcium binding properties. This carboxylation step requires reduced vitamin K 
as a cofactor. It is provided and recycled in the so called vitamin K cycle, which consists of 
the vitamin K epoxid reductase (VKOR), DT-diaphorase and γ-glutamyl carboxylase 
(GGCX). The VKOR is inhibitable by warfarin and other coumarins. High levels of 
uncarboxylated MGP (ucMGP) were found in VSMC after treatment with vitamin K 
antagonists like warfarin, which is frequently used for anticoagulation. Besides MGP, other 
vitamin K dependent proteins are known. One is the Gas6 protein, which is also expressed by 
VSMC, but its role is not yet fully understood. Gas6 binds to the Axl receptor, a receptor 
tyrosine kinase which gets autophosphorylated after binding to its ligand. Gas6 offers one n-
terminal carboxylation site. The effects of uremia on vitamin K recycling via the vitamin K 
cycle are unknown. 
Aim of this thesis was to characterize the activities of three enzymes of the vitamin K cycle 
and the role of vitamin K dependet Gas6 protein under uremic conditions.  
First, a fluorescence method for the quantification of GGCX activity in vitro in tissue samples 
was developed. This method employs a fluorescein isothiocyanate (FITC) labelled Glu 
containing hexapeptide which gets carboxylated by the GGCX. The generated Gla-peptide 
can be easily quantified using a reversed phase HPLC setup. For further proteomic analysis 
mass spectrometry was applied.  
Second, the influences of uremia and pharmacological doses of vitamin K supplementation on 
the activity of the vitamin K cycle and extraosseous calcification were investigated. Uremia 
was induced in rats by adenine diet, in part supplemented with vitamin K1 or K2 for 4 or 7 
weeks. After 4 weeks of adenine, the activity of the vitamin-K cycle enzyme GGCX but not 
DT diaphorase or VKOR was reduced. Serum levels of ucMGP increased, indicating 
functional vitamin K deficiency. No histological calcification was detected at this stage but 
aortic and renal calcium content increased. Seven weeks of adenine induced histological 
calcification in the aorta, heart and kidneys. The addition of vitamin K restored the intrarenal 
gamma-carboxylase activity and over-stimulated it in the liver and aorta. Moreover, vitamin 
K treatment decreased tissue calcium content. Uremic functional vitamin K deficiency, at 
least results from a reduction of the gamma-carboxylase activity which possibly contributes to 
calcification.  
Third, the influence of Gas6 protein on vascular calcification was investigated in murine in 
vitro VSMC culture and different in vivo models using a) Warfarin diet, b) uninephrectomy or 
c) electrocautery of the kidney as well d) ageing mice.  
In vitro VSMC exposed to warfarin calcified and showed increased apoptosis without 
differences between wildtype (WT) and Gas6-/- mice. In vivo, after electrocautery, serum 
calcium increased similarly in WT and Gas6-/- mice but no significant difference in aortic 
calcium content was observed between the groups. In all groups von Kossa staining revealed 
only a weak positive vascular staining in WT and Gas6-/- mice. In ageing mice no significant 
differences in vascular calcification could be identified between Gas6-/- and WT mice. No 
differences were found in left ventricular (LV) mass, stroke volume or pulse wave velocity 
(PWV) in all treatment groups. Gas6-/- mice showed no up regulation of MGP. This does not 
support a role of Gas6 in the pathogenesis of vascular calcification.  
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Zusammenfassung 
Vaskuläre Kalzifizierung tritt als eine Begleiterscheinung von Atherosklerose, Alter, 
chronischen Nierenerkrankungen und Diabetes auf und geht mit einer stark erhöhten 
Morbidität und Mortalität einher. Arterielle Kalzifizierungen erfolgen in der Tunica intima 
und der Tunica media. Hier transdifferenzieren glatte Gefäßmuskelzellen (vascular smooth 
muscle cells, VSMC) in einen osteoblastären Phänotyp. Entgegen der tradierten Auffassung, 
dass die Gewebeverkalkung ein passiver Prozess ist, weiß man nun, dass es sich um einen 
aktiv regulierten Prozess handelt. Es konnten regulierbare Verkalkungsinhibitoren identifiziert 
werden. Ein potenter Kalzifizierungsinhibitor ist das Matrix Gla Protein (MGP), welches 
insbesondere in der Gefäßwand von VSMC exprimiert wird. MGP wird an 5 Glutamatresten 
posttranslational γ-carboxyliert, wodurch eine Kalziumbindung ermöglicht wird. Zur γ-
Carboxylierung wird reduziertes Vitamin K als Cofaktor benötigt. Dieses wird im 
sogenannten Vitamin K Zyklus bereitgestellt und recycelt. Die beteiligten Enzyme sind die 
Vitamin K Epoxid-Reduktase (VKOR), DT-Diaphorase und γ-glutmayl-Carboxylase 
(GGCX). Die VKOR wird durch Coumarine wie Warfarin inhibiert.  
Erhöhte Level an uncarboxyliertem MGP (ucMGP) werden in VSMCs nach Warfarin 
Exposition gefunden, welches weitverbreitet therapeutisch als Antikoagulanz Einsatz findet. 
Neben MGP sind weitere Vitamin K abhängige Proteine bekannt. Hierzu zählt auch das Gas6 
Protein, welches ebenfalls von VSMC exprimiert wird, aber dessen Funktion noch nicht 
vollständig geklärt ist. Gas6 bindet an den Axl-Rezeptor, eine Rezeptor-Tyrosinkinase die 
nach Ligandenbindung autophosphoryliert wird. Gas6 verfügt über einen n-terminale Gla 
Rest. Das Ziel dieser Arbeit war die Charakterisierung der Enzymaktivitäten im Vitamin K 
Zyklus und die Rolle des Vitamin K abhängigen Gas6 Proteins in der experimentellen 
Urämie.  
Dazu wurde zunächst eine Fluoreszenz-gestützte Methode entwickelt, zur Bestimmung der 
GGCX Aktivität in Gewebeproben. Verwendet wurde ein Fluorescein Isothiocanat (FITC) 
gekoppeltes Glu-haltiges Hexapeptid, welches durch die GGCX carboxyliert wird. Ein 
reversed phase (rp) HPLC gestütztes Setup ermöglicht eine einfache Qunatifizierung des 
generierten Gla-Peptids. Zur weiterführenden Proteom-Analyse wurde eine 
Massenspektometrie durchgeführt.  
Zweitens wurde der Einfluss einer Urämie sowie  die Verabreichung pharmakologischer 
Dosen Vitamin K auf die Enzyme des Vitamin K Zyklus und extraossäre Kalzifikation 
untersucht. Durch Gabe von Adenin über einen Zeitraum von 4 oder 7 Wochen wurde in 
Ratten eine Urämie induziert, teilweise unter Supplemtentation mit Vitamin K1 oder K2. Nach 
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4-wöchiger Adenin Behandlung war die Aktivität der GGCX reduziert, nicht jedoch der DT-
Diaphorase oder der VKOR. Die Serumwerte von ucMGP waren erhöht, woraus auf eine 
funktionale Vitamin K Defizienz geschlossen werden kann. Histologisch konnte keine 
Kalzifiaktion nachgewiesen werden, es zeigten sich jedoch erhöhte renale und aortale 
Calcium Gehalte. Eine 7-wöchige Verabreichung von Adenin induzierte histologische  
Kalzifikation von Aorta, Herz und Niere. Durch Zugabe von Vitamin K wurde die erniedrigte 
renale GGCX Aktivität zurückgesetzt und in Leber und Aorta überstimuliert. Darüber hinaus 
senkte Vitamin K den Gehalt an Calcium im Gewebe. Möglicherweise resultiert die 
funktionale Vitamin K Defizienz in urämischen Patienten zum Teil aus einer erniedrigten 
GGCX Aktivität mit einhergehenden Kalzifikationen.  
Drittens wurde der Einfluss des Gas6 Proteins auf die Gefäßkalzifikation in murinen in vitro 
VSMC Kultur und in verschiedenen in vivo Modellen untersucht: a) Warfarin Diät b) 
Uninephrektomie c) Elektrokoagulation der Niere sowie d) alternde Mäuse. In vivo erhöhte 
sich nach Elektrokauterisation der Serum Calcium Gehalt in WT und Gas6-/- ohne 
signifikanten Unterschied zwischen den Gruppen. In allen Gruppen zeigte sich lediglich eine 
schwach positive vaskuläre von Kossa Färbung in WT und Gas6-/- Mäusen. In alternden, 
unbehandelten Mäusen gab es keine signifikanten Unterschiede bezüglich vaskulärer 
Kalzifikation zwischen WT und Gas6-/- Mäusen. Echokardiographisch zeigten sich keine 
Unterschiede in der linksventrikulären (LV) Masse, Schlagvolumen oder 
Pulswellengeschwindigkeit (PWV) in allen behandelten Gruppen. In Gas6-/- Mäusen lag keine 
Heraufregulierung von MGP vor. Diese Daten unterstüzen keine Rolle von Gas6 in der 
Pathogenese der vaskulären Kalzifikation.  
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1.1 General Introduction 
Fat soluble vitamin K exists in 4 major different forms, all based on the 2-methyl 1,4-
naphtochinon (K3). The phylloquinone (K1; Figure 1), a 3 phytyl substituent, is located in 
membranes of chloroplasts. It is the major component of vitamin K uptake in human nutrition.  
 
 
Figure 1: Chemical structure of phylloquinone (Vitamin K1) 
 
High contents of vitamin K1 can be found for example in herbs (cress: 600 µg/100 g; chive: 
570 µg/100 g ), green leafy vegetables (corn salad: 200; chard 441 µg/100 g) or broccoli (129 
µg/100 g) (1). Menaquinones (K2) contain an unsaturated isoprenoid side chain at the C3 
position (MK4 - MK10, Figure 2).  
 
 
Figure 2: Chemical structure of menaquinone 4 (MK4) 
 
They are formed by bacterial fermentation, for example by bacillus subtilis in natto (2). Natto, 
made from fermented soy beans, is the richest known source of vitamin K2. Menadione (K3) 
and menadione esther (K4) are synthetic compounds and play only a role in animal nutrition. 
Vitamin K1 is mainly found in the liver to serve as a cofactor for γ-carboxylation of the blood 
coagulation factors II, VII, IX, X, protein C and S (3). Vitamin K2 is mainly distributed in 
extrahepatic tissues (4) and contributes to γ-carboxylation of vitamin K dependent proteins 
like MGP, Osteocalcin (Ocn) or Gas6. The function of all vitamin K dependent proteins is 
mediated by binding of calcium to the γ-carboxylated form (5). Increased amounts of 
uncarboxylated prothrombin (PIVKA), Ocn and MGP were detected in dialysis patients 
compared to healthy controls (6;7). This indicates a functional vitamin K deficiency in this 
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population. The origin of the functional vitamin K deficiency in CKD is only partially 
understood. Reduced vitamin K intake has been described in dialysis patients (7) but we 
reasoned that this cannot fully explain the marked functional vitamin K deficiency.   
Low levels of carboxylated MGP predict mortality in such patients (6;8). MGP knockout mice 
develop spontaneous calcification of arteries (9). The mechanism by which MGP inhibits 
vascular calcification may involve BMP-2 antagonism and a direct calcium-complexing effect 
(10). MGP is expressed predominantly by vascular smooth muscle cells (VSMC) in the 
arterial media and chondrocytes. It contains five glutamic acid residues that can be γ-
carboxylated (Glu → Gla) by the vitamin K-dependent γ-carboxylase (GGCX). MGP potently 
inhibits precipitation of hydroxyapatite crystals in uremia. Abnormalities in mineral 
metabolism and vascular calcification are highly present in chronic kidney diseases (CKD) 
(11). Increased ucMGP is associated with increased coronary artery calcification (12). 
Calcification can occur at the intimal (atherosclerosis) or at medial layer (arteriosclerosis) of 
an arterial vessel wall (13). In CKD, defined as a decreased kidney function with a glomerular 
filtration rate < 60 mL/min per 1.73 m2 (14), the arterial tunica media gets predominantly 
calcified (13). It can be visualized by computed tomography (13;15). An increased coronary 
artery calcification score is highly related to mortality in haemodialysis patients, independent 
of the traditional risk factors (16). Possible unique contributors to the development of vascular 
calcification in CKD are an increased calcium-phosphate product, parathyroid hormone and 
as well as reduced levels of inhibitors of vascular calcification like fetuin-A and insufficient 
activity of MGP (17).  
In contrast to MGP, the role of Gas6 in vascular calcification is not well established. Vitamin-
K dependent carboxylation of  Gas6 is essential for its binding to the Axl receptor (18). 
Tyrosine phosphorylation of Axl induces cell proliferation (19). Gas6 is known to protect 
endothelial cells and VSMC against apoptosis (20;21), the latter is known to be associated 
with vascular calcifications. Another potential link between Gas6 and vascular calcification is 
demonstrated by in vitro data showing that phosphate- induced calcification of VSMC is 
associated with a downregulation of Gas6 expression (21). In addition, antiapoptotic effects 
and protection of calcification of VSMC by statins were mediated through Gas6 mRNA 
stabilization (21). So far no in vivo data are available on the role of Gas6 in vascular 
calcification. To clarify this, I assessed Gas6 knockout (Gas6-/-) mice and Gas6-/- derived 
VSMC in in vitro and in vivo vascular calcification models.  
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Existing animal models contribute to a better understanding of the pathogenesis in vascular 
calcification processes. Experimental uremia can be created by reducing the kidney mass 
(uninephrectomy, 5/6 nephrectomy, electrocautery), which mimics the progressive nephron 
loss occurring in patients with chronic renal failure (22;23). Noninvasively, dietary adenine 
causes an overload of the converting adenine phosphoribosyltransferase and leads to 
deposition of 2,8 dihydroxyadenosine crystals in the tubulo-interstitium of the kidney (22;23). 
Another approach to induce vascular calcification is oral administration of coumarins like 
warfarin (Figure 3) or phenprocoumon. This was shown both in rats (24) and humans (25) 
(26). Coumarins directly inhibit the activity of the vitamin K oxidoreductase (VKOR; EC 
1.1.4.1)(27). This leads to an insufficient activation of blood coagulation factors, a desirable 
effect for patients with artificial heart valves or after thromboembolism. But the drawback is a 
lesser γ-carboxylation of extrahepatic proteins like the vessel derived calcification inhibitor 
MGP. Replacing coumarins with alternative thrombin inhibitors is under actual debate 
(28;29). In turn, a high intake of vitamin K2 (MK4) was capable of regressing warfarin-
induced medial calcification in Wistar rats (30). 
 
Figure 3: Chemical structure of warfarin 
 
The GGCX (EC code 4.1.1.90) is an intrinsic membrane protein located in the endoplasmic 
reticulum and requires vitamin K as a cofactor (31). It utilizes both reduced vitamin K (KH2) 
and vitamin K with KH2 being the more potent one (32) (Figure 4). The amino terminus is 
located on the cytoplasmic side and its carboxyl terminus on the lumen (33). The enzyme 
carboxylates specific protein bound glutamate residues at the gamma position resulting in an 
extra negative charge and thus potent calcium binding site (34).  
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Figure 4: The gamma-carboxylation step: A peptide gets γ-carboxylated by the GGCX, which 
requires the reduced form of vitamin K (Vit KH2) as a cofactor. KH2 is epoxidized to vitamin 
K epoxide (Vit K>O). 
 
Multiple proteins require γ-carboxylation to achieve full bioactivity (35). The pro-sequence, 
which is the enzyme binding site, is a homologous region of several vitamin K dependent 
proteins (3). Some known proteins containing this pro-sequence and thus being targets for the 
GGCX are prothrombin, protein S and extrahepatic osteocalcin, Gas6 and MGP (5). Besides 
the availability of vitamin K and KH2, the GGCX activity is also dependent on the 
concentration of substrate and NaHCO3 (36). The enzymatic reaction produces the unusual 
aminoacid Gla and vitamin K epoxide (K>O) as products, whereby K>O is recycled to K and 
KH2 by the warfarin sensitive VKOR (37;38). The latter product is also generated by a 
warfarin insensitive antidotal enzyme (39) the DT-diaphorase (EC 1.6.99.2 also called 
NADPH-quinone oxidoreductase). The DT diaphorase using NAD(P)H as an electron 
acceptor uses vitamin K as a substrate and is independent to the dithiotreitol pathway, which 
antagonises the effects of warfarin (40;41). The DT-diaphorase is predominantly active in the 
liver and offers an alternative pathway to provide vitamin KH2. Dicoumarol (Figure 5) 
inhibits the purified DT-diaphorase by binding to the oxidized form of the enzyme (42). 
 
Figure 5: Chemical structure of dicoumarol 
 
 
GGCX 
Vit KH2 
Vit K>O 
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These three enzymes form the so called vitamin K cycle (Figure 6) (43;44). 
   
 
              
Figure 6: The vitamin K cycle (modified from Stafford, 2005 (43)). The required cofactor 
vitamin KH2 for the γ-carboxylation by the GGCX is stepwise recycled by 2 additional 
enzymes: the VKOR, which is directly inhibitable by warfarin and the DT-diaphorase. 
 
In 1975, Emson and Suttie developed a method for measuring the GGCX activity by 
incorporation of radioactive H14CO3- in the synthetic peptide Phe-Leu-Glu-Glu-Leu (short: 
FLEEL) which is based on the sequence of prothrombin (31). Ulrich and colleagues tested 16 
peptide sequences as enzyme substrates and found FLEEL to be the most active one (45). The 
peptides were hydrolyzed and purified by anion exchange HPLC. Quantification was 
achieved using a setup based upon a liquid scintillation for detection (46). Protocols describe 
the addition of propeptide in approaches with purified enzyme (47) or in tissues without 
propeptide (31;32;48). In vitro, GGCX is inhibited by N-Ethylmaleimide (NEM) (49) and 5-
Mercapto-1-Methyl-Thiotetrazole (5-MMT), which is used as a part of antibiotics 
(moxalactam) (50). 
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1.2 Aims 
1. Establishment of an appropriate method for safe and reproducible detection of γ-
glutamyl-carboxylase activity in different tissues  
2. Development of a model for uremia and vascular calcification in rats  
3. Investigation of the vitamin K cycle under the conditions of uremia in rats 
4. Analysis of the influence of oral vitamin K supplementation on vascular calcification  
5. Investigation of the influence of oral vitamin K supplementation on vitamin K 
dependent enzyme activities  
6. Examination of the influence of uremic toxins on the activity of the γ -glutamyl 
carboxylase activity  
7. To clarify the role of Gas6 protein in vascular calcification processes  
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2 MATERIALS AND METHODS 
 
2.1 Chemicals 
 
Acetic Acid  Merck, Darmstadt, Germany 
Acetonitrile, HPLC grade AppliChem, Darmstadt, Germany 
Agarose Cambrex, ME, USA 
Agilent RNA 6000 Nano Kit Agilent, Böblingen, Germany  
AgNO3 Merck, Darmstadt, Germany 
ALT lysis buffer  Qiagen, Hilden, Germany 
Ambion RNase Zap Life Technologies, Darmstadt, Germany 
BCA Pierce Protein Determination Kit 
Fisher Scientific GmbH, Schwerte, 
Germany 
BSA Serva, Heidelberg, Germany 
Calcium Phosohate Sigma Aldrich, Munich, Germany 
CAPS Sigma Aldrich, Munich, Germany 
Collagenase Sigma Aldrich, Munich, Germany 
Complete Mini Protease Inhibitor Cocktail Roche, Diagnostics, Mannheim, Germany 
Dicoumarol AppliChem, Darmstadt, Germany 
Diethylether, HPLC grade Sigma Aldrich, Munich, Germany 
Digitonin AppliChem, Darmstadt, Germany 
DNase Qiagen, Hilden, Germany 
DTT AppliChem, Darmstadt, Germany 
EDTA AppliChem, Darmstadt, Germany 
Elastase Sigma Aldrich, Munich, Germany 
Ethanol  
Apotheke, Universiätsklinikum Aachen, 
Germany 
Ethanol HPLC grade Sigma Aldrich, Munich, Germany 
Ethidiumbromide Sigma Aldrich, Munich, Germany 
FAD AppliChem, Darmstadt, Germany 
Fermentas gene Ruler DNA ladder SM 0313 
Fisher Scientific GmbH, Schwerte, 
Germany 
FLEFLK-FITC Biomatik, Ontario, Canada 
Formalin Merck, Darmstadt, Germany 
Formic acid Merck, Darmstadt, Germany 
Gentamycin Sigma Aldrich, Munich, Germany 
GGCX TaqMan® gene expression assay 
RN00582138 Life Technologies, CA, USA  
Glucose-6-phosphate AppliChem, Darmstadt, Germany 
Glucose-6-phosphate-dehydrogenase  AppliChem, Darmstadt, Germany 
H2O2 AppliChem, Darmstadt, Germany 
HEPES AppliChem, Darmstadt, Germany 
Histofix  Carl Roth, Karlsruhe, Germany 
Imidazole AppliChem, Darmstadt, Germany 
In situ Cell Death Detection Kit Roche, Basel, Switzerland 
Indoxylsulphate AppliChem, Darmstadt, Germany 
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Isoflurane Abbott, IL, USA 
Isopropanol Sigma Aldrich, Munich, Germany 
KCl AppliChem, Darmstadt, Germany 
Ketamin 10% 
CEVA Tiergesundheit, Düsseldorf, 
Germany 
Liquid nitrogen 
Apotheke, Universiätsklinikum Aachen, 
Germany 
Meandione AppliChem, Darmstadt, Germany 
Meanquinone 4 Sigma Aldrich, Munich, Germany 
Methanol AppliChem, Darmstadt, Germany 
MnCl2 Carl Roth, Karlsruhe, Germany 
MTT Merck, Darmstadt, Germany 
Na2HCO3 Merck, Darmstadt, Germany 
NaCl AppliChem, Darmstadt, Germany 
NaCl, 0.9% Delta Select, Pfullingen, Germany 
NADPH AppliChem, Darmstadt, Germany 
NaHCO3 Merck, Darmstadt, Germany 
NaOH Merck, Darmstadt, Germany 
Paraffin Carl Roth, Karlsruhe, Germany 
PBS Gibco, Gaithersburg, MD, USA 
PCR beads Ready to go  GE Healthcare, Munich, Germany 
p-Cresol AppliChem, Darmstadt, Germany 
Penicillin Sigma Aldrich, Munich, Germany 
Phylloquinone Sigma Aldrich, Munich, Germany 
Picric Acid Sigma Aldrich, Munich, Germany 
Proteinase K Qiagen, Hilden, Germany 
qPCR Core Kit for SYBR Green I RT SN10-05 Eurogentec, Cologne, Germany 
qPCR Core Kit for SYBR Green I RT SN10-05 Eurogentec, Cologne, Germany 
Randox Cresophthalein Assay Randox Laboratories, Crumlin, UK 
Reverse Transcriptase Core Kit RT-RTCK-05 Eurogentec, Cologne, Germany 
Reverse Transcriptase Core Kit RT-RTCK-05 Eurogentec, Cologne, Germany 
RNA later Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
Rotihistol Carl Roth, Karlsruhe, Germany 
Safranin-O  Sigma Aldrich, Munich, Germany 
Sirius Red Sigma Aldrich, Munich, Germany 
Smooth Muscle Cell (SMC) Growth Medium 2  PromoCell GmbH, Heidelberg, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodiumthiosulfate Sigma Aldrich, Munich, Germany 
Streptomycin Sigma Aldrich, Munich, Germany 
Sucrose Carl Roth, Karlsruhe, Germany 
Supplement Pack for SMCs PromoCell GmbH, Heidelberg, Germany 
Tetra-butyl-ammoniumphosphate Sigma Aldrich, Munich, Germany 
Tissue Tek Sakura, Alphen, Netherlands 
Trifluoroacetic acid Carl Roth, Karlsruhe, Germany 
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Tris-Cl BioRad, Munich, Germany 
TritonX AppliChem, Darmstadt, Germany 
Trypsin/ EDTA GIBCO, Gaithersburg, MD, USA 
Tween 20 Sigma Aldrich, Munich, Germany 
Urea BioRad, Munich, Germany 
Vectashield with DAPI Vector Laboratories, CA, USA 
Warfarin Sigma Aldrich, Munich, Germany 
Xylazin 2% Medistar, Ascheberg, Germany 
Xylol AppliChem, Darmstadt, Germany 
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2.2 Instruments  
 
7500 Real-Time PCR TagMan® system Life Technologies, CA, USA 
Agilent 1100 Series HPLC apparatus  Agilent Technoligies, Böblingen, Germany 
Agilent auto sampler G 1313A, Agilent Technoligies, Böblingen, Germany 
Agilent binary gradient pump G 1312A Agilent Technoligies, Böblingen, Germany 
Agilent vacuum degasser G 1379A Agilent Technoligies, Böblingen, Germany 
Balance Sartorius 2007 MP Sartorius AG, Göttingen, Germany 
Centrifuge 4K15 Sigma Aldrich, Munich, Germany 
Centrifuge 5417R Eppendorf, Hauppauge, NY, USA 
CODA blood pressure system  
Kent Scientific, Torrington, Connecticut, 
USA 
Cooling plate COP 30 Medite GmbH, Burgdorf, Germany 
Cryotome Leica Jung CM3000 Leica Biosysteme, Nussloch. Germany  
Erbotom ACC 450 Erbe, Tübingen, Germany  
Freezer Jouan VXE600 Fisher Scientific GmbH, Schwerte, Germany 
HPLC autoinjector L-7200 Merck Hitachi, Tokyo, Japan 
HPLC column oven L-7350 Merck Hitachi, Tokyo, Japan 
HPLC fluorescence detector L-7480 Merck Hitachi, Tokyo, Japan 
HPLC interface D-7000 Merck Hitachi, Tokyo, Japan 
HPLC pump L-7100 Merck Hitachi, Tokyo, Japan 
HPLC UV detector L-7400 Merck Hitachi, Tokyo, Japan 
Incubator Heracell Fisher Scientific GmbH, Schwerte, Germany 
Lyophilisator, Christ Loc 1mALPHA 1-4  Martin Christ, Osterode am Harz, Germany 
Max RP HPLC C12 column Phenomenex, Aschaffenburg, Germany 
Microscope 
Olympus Deutschland GmbH, Hamburg, 
Germany  
Microscope Leica DM 6000 B Leica Biosysteme, Nussloch. Germany  
MilliQ Water system Millipore GmbH, Schwalbach, Germany 
MS1 Minishaker IKA, Staufen, Germany 
Multifuge 3L-R Heraeus Instruments, Hanau, Germany 
Orbital Shaker Forma Scientific Inc., Marietta, OH, USA 
Paraffin Section Mounting Bath Barnstead International, Iowa, USA 
pH-Fix 0-14 Carl Roth, Karlsruhe, Germany 
Qiagen tissue lyser  Qiagen, Hilden, Germany 
Rotary Microtome Slee Cut 5062 SLEE medical GmbH, Mainz, Germany 
Sciex API 3000 LC/MS/MS system Life Technologies, CA, USA 
Tecan sunrise microplate absorbance reader Tecan, Männedorf, Switzerland 
Therma Sonic Gel warmer Parker Laboratories, Fairfield, NJ, USA 
Thermocylcer PTC-100 MJ Research Inc., Quebec, Canada 
Tissue embdding station Leica 1160 Leica Biosysteme, Nussloch. Germany  
Tissue processor Slee mtm SLEE medical GmbH, Mainz, Germany 
Ulracentrifuge Optima L-100 XP Beckman Coulter GmbH, Krefeld, Germany 
Vacuum hybrid pump RL 6  Vacubrand, Wertheim, Germany 
Vevo 770 Visualsonics, Ontario, Canada 
Vitros 250 Ortho Clinical Diagnostics, NY, USA 
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2.3 Materials 
 
Blood sample tube with serum gel, 1.1 ml Sarstedt AG und Co, Nümbrecht, Germany 
Cell culture flask, T25, T75 Becton Dickinson, Heidelberg, Germany 
Cell scraper  Becton Dickinson, Heidelberg, Germany 
Centrifugation tube Beckman Coulter GmbH, Krefeld, Germany 
Costar Stripette, 5 ml, 10 ml, 25 ml Fisher Scientific GmbH, Schwerte, Germany 
Cover glass Engelbrecht GmbH, Edermünde, Germany 
Depilatory cream Veet, Reckitt Benckiser, Hull, UK 
Dewar  KGW Isotherm, Karlsruhe, Germany 
Disposable Scalpels, No 15, No 23 Feather, Osaka, Japan 
Electrocoagulation Ball Tip Erbe, Tübingen, Germany 
Embedding cassettes Carl Roth, Karlsruhe, Germany 
Eppendorf pipettes Eppendorf AG, Hamburg, Germany 
F-Air canister  Harvard Apparatus, Holliston, MA, USA 
Filter, 0.2 µM Millipore GmbH, Schwalbach, Germany 
Flange cap N11 Macherey Nagel, Düren, Germany 
Forceps 
Fine Science Tools GmbH, Heidelberg, 
Germany 
Glass pipettes  Sarstedt AG und Co, Nümbrecht, Germany 
HPLC C-12 Synergy 4 µm Max-RP 80A 
column  Phenomenex, Aschaffenburg, Germany 
HPLC C-12, 4 x 3 mm, guard column  Phenomenex, Aschaffenburg, Germany 
Micro Inserts, 200 µl Macherey Nagel, Düren, Germany 
Microlance 21G Becton Dickinson, Heidelberg, Germany 
Microscope slide Superfrost plus Fisher Scientific GmbH, Schwerte, Germany 
Microtiterplate, 12-well, 96-well Becton Dickinson, Heidelberg, Germany 
Microtome Blade, N35, C35 Feather, Osaka, Japan 
Pipetboy 
IBS Integra Biosciences GmbH, Fernwald, 
Germany 
Pipette tips  Carl Roth, Karlsruhe, Germany 
Rat Restrainer Kent Scientific, Torrington, Connecticut, USA 
Round bottom flask Carl Roth, Karlsruhe, Germany 
Safety Multifly Canuele Sarstedt AG und Co, Nümbrecht, Germany 
Scissors 
Fine Science Tools GmbH, Heidelberg, 
Germany 
SepPak C18 cartridge Waters GmbH, Eschborn, Germany 
Silk, 3-0 Mersilene, Ethicon 
Johnson & Johnsons, St Stevens-Woluwe, 
Belgium 
Stainless steel beads 5 mm Qiagen, Hilden, Germany 
Syringes, plastic, 1 ml;  Becton Dickinson, Heidelberg, Germany 
Syringes, plastic, 10 ml; 20 ml Terumo, Eschborn, Germany 
Tissue Tek Cryomold Sakura, Alphen, Netherlands 
Tubes 1.5; 2 ml Eppendorf AG, Hamburg, Germany 
Tubes 15mL, 50 ml 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Tubes, N11, 1.5 ml, glass Macherey Nagel, Düren, Germany 
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Ultrasound Gel 
A + M Handelsvertretung, Versmold, 
Germany 
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2.4 Software 
 
ChemSketch 12.01 ACD labs, Ontario, Canada 
Coda Kent Scientific, Torrington, Connecticut, USA 
Diskus C.H. Hilgers, Königswinter, Germany 
Graph Pad Prism 5.01 GraphPad Software, Inc., CA, USA 
Image J 1.43u National Institute of health, MD, USA 
Merck-Hitachi D-7000 HSM  Merck Hitachi, Tokyo, Japan 
Origin Pro 8 OriginLab Corporation, MA, USA 
Vevo Visualsonics, Ontario, Canada 
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2.5 Methods for Aim 1 
 
2.5.1 Peptide design 
The synthetic fluorescence labelled hexapeptide FLEFLK-FITC (purity > 90%) was 
synthesized by Biomatik Corporation, Ontario Canada. The peptide was designed in order to 
contain only one carboxylation site instead of two, with good purification and solubility 
properties. The lysine residue is required to link the fluorescence marker (FITC) to the side 
chain of the peptide (Figure 7).  
                 
 
Figure 7: Chemical structure of the FITC labelled hexapeptide FLEFLK. The brackets 
indicate the site of γ-carboxylation. 
 
2.5.2 Animals 
Animals received food and water ad libitum. They were housed in a 12h day and night cycle 
(Institut für Versuchstierkunde, Aachen, Germany).  
All animals were treated in accordance with the requirements of the Federation of the 
European Laboratory Animals Science Associations approved by the Landesamt für Natur, 
Umwelt und Verbraucherschutz NRW, Germany (Permit No 84-02.04.2011.A144). For 
preparation of microsomes healthy, male WISTAR rats (purchased from Charles River, 
Sulzfeld, Germany) weighing 462 +/- 30 g were used. Animals were sacrificed under 
isoflurane anaesthesia by heart puncture and exsanguination. Before harvesting, organs were 
perfused in vivo with 20 ml ice-cold PBS.   
 
2.5.3 Preparation of microsomes 
After removal the liver, kidneys and aortas were immediately snap frozen in liquid nitrogen 
and stored at -80°C. To isolate the enzyme rich microsomes 300-400 mg of liver or kidney 
F              L                  E (Gla)         F                   L              K
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was used. Aortas were pooled (3 ± 1 aortas) up tp 150 mg in total. All tissue samples were cut 
into small pieces and homogenized in a Qiagen tissue lyser in 3 x volume of 300 mM sucrose 
buffer (10 mM HEPES, 0.1 mM EDTA and protease inhibitor cocktail) for 2 x 2 min at 24 Hz 
with two 5 mm steel beads. Afterwards the homogenate was centrifuged at 1,600 × g, for 10 
min at 4°C. The pellet was discarded and the supernatant was collected and centrifuged for 20 
min at 10,000 × g. The post-mitochondrial fraction was ultracentrifuged at 100,000 × g for 1 h 
at 4°C. The pelleted microsomal fractions were dissolved in 0.3 ml sucrose buffer in a protein 
concentration of 5-15 mg/ml, aliquoted and flash frozen for storage at -80°C. Microsomes 
from aortas were diluted in 100 µl sucrose buffer. 
 
2.5.4 Protein determination 
Protein content of microsomes from rat liver, kidney or aorta was determined by the BCA 
Pierce kit accordong to the manufacturer’s protocol. Each 25 µl sample was measured in 
duplicates. BSA standard concentrations were 2, 1.5, 1, 0.75, 0.5, 0.25, 0.125 and 0.025 
mg/ml. The samples were incubated for 30 min at 37°C. The absorption was measured at 562 
nm on a Tecan sunrise microplate absorbance reader. 
 
2.5.5 GGCX  activity assay from microsomes 
The assay was performed in sealed tubes at 20°C. A total reaction volume of 0.125 ml 
contained 250 µg microsomal protein, 0.5% (w/v) CAPS, 5 mM DTT, 2.5 mM NaHCO3, 10 
mM MnCl2,100 µg/ml vitamin K1H2, at pH 7.0. The pipetting scheme was 1) 64 µl of 250 µg 
microsomal protein, 2) 12.5 µl of 50 mg/ml CAPS, 3) 2 µl of 625 mM DTT, 4) 12.5 µl of 25 
mM NaHCO3, 5) 12.5 µl of 100 mM MnCl2 and 6) 12.5 µl of 1 mg/ml vitamin K1H2 . All 
substrates were added in aqueous solution, except vitamin K1H2, which was diluted 1 mg/ml 
in ethanol. The reaction was started by adding 2 mM FLEFLK-FITC, always protected from 
light. After 30 min the reaction was stopped by adding 2 x volume of ice-cold methanol. All 
samples were kept on ice until injection. For enzyme kinetics the reaction was stopped at 0, 
15, 60 and 120 min. The microsomal protein contents were 50, 125, 250, 500 and 750 µg. 
Used concentrations of the substate FLEFLK-FITC were, 0.5, 1, 2, 4 and 5 mM. To inhibit 
enzyme activity, 10 mM NEM was added to the reaction mixture prior to adding the substrate 
FLEFLK-FITC (2 mM). Vitamin K1 was reduced to KH2 by incubation in a mixture of 20 
mM DTT, 50 mM NaCl and 2 mM Tris at 37°C for 24 h in the dark. (47). The resulting K1H2 
was extracted with 100% ether, diluted up to 1 mg/ml in ethanol and stored at -80°C in argon 
atmosphere. All chemicals used here were HPLC grade. 
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2.5.6 Purification of FLELFK-FITC after in vitro carboxylation 
Purification of the carboxylated peptide was achieved by the method of Mc Tigue (46). The 
reaction mixture of the GGCX assay was centrifuged at 10,000 × g for 15 min. For mass 
spectrometry (MS) measurements, the supernatant was dissolved in 10 ml SI-buffer (250 mM 
sucrose, 25 mM imidazole, 5 mM tetra-butyl-ammoniumphosphate), loaded onto a Waters 
SepPak C18 cartridge and washed with additional 10 ml of SI-buffer. The peptide was eluted 
in 4 ml methanol, which was evaporated by drying at 50°C in argon flow. For final HPLC 
measurements, samples were centrifuged at 10,000 × g for 15 min at 4°C. The supernatant 
was collected and the remaining residue was washed twice with a water-acetonitrile solution 
(4:1) and pooled with the supernatant to a total volume of 1 ml. 
 
2.5.7 Reversed phase HPLC 
The D-7000 Merck-Hitachi HPLC consisted of a pump (L-7100), an autoinjector (L-7200), a 
column oven (L-7350), a fluorescence detector (L-7480) and an interface (D-7000). 50 µl of 
each sample was injected. A linear gradient from 100% of 0.1% (v/v) TFA in H2O up to 100 
% 0.1% TFA (v/v) in acetonitrile was set at a continuous flow of 0.5 ml/min. For separation, a 
Phenomenex C-12 Synergy 4 µm Max-RP 80A column including a C-12, 4 x 3 mm, 
Phenomenex guard column was used. Fluorescence detection was optimized for FITC at 494 
nm excitation and 521 nm emission The pressure limit was set at 350 bar. Each run was 
recorded for 30 minutes on the Merck-Hitachi D-7000 HSM software. The peptide was 
quantified by using internal and external standards. 
 
2.5.8. Mass spectrometric confirmation by LC/ESI-MS 
Liquid chromatography was carried out on an Agilent 1100 Series HPLC apparatus consisting 
of an auto sampler G 1313A, a binary gradient pump G 1312A and an Agilent vacuum 
degasser G 1379A. The gradient of the mobile phase, column and injection volume were 
equal to the rp-HPLC setup. The mass spectrometric detection was performed on an Applied 
Biosystems Sciex API 3000 LC/MS/MS system in ESI-positive mode. An electrospray needle 
voltage of + 4,500 V in the positive ion mode and nitrogen as nebulizer were used The turbo 
heater gas (450°C) was set to a pressure of 65 psi and the curtain gas was set to 58 psi. Mass 
spectra were acquired in full scan mode between m/z 350-1,250. Resolution of the mass 
spectrometer was set to “unit”. Peptide molecular weights were calculated using chemSketch. 
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2.5.9 14CO2 incorporation 
The 14CO2 incorporation of FLEEL is the standard assay to determine GGCX activity by a 
liquid scintillation counter. The 14CO2 incorporation by FLEFLK-FITC was measured by 
Vasantha P. Mutucumarana at the University of North Carolina at Chapel Hill, North 
Carolina, USA, as described previosly (51). The radioactive assay was performed for 1 h 20 
min. The kcat/KM of the 14CO2 incorporation into FLEFLK-FITC was calculated by 
conversion of the Michaelins Menten equation (Formular 1a-f). 
 
Formular 1a      v = Vmax [S] / (KM + [S]) 
 
Formular 1b  Vmax = kcat [E] 
 
Formular 1c               v = kcat [E] [S] / (KM + [S]) 
 
at low [S], that is when Km >> [S}, 
 
Formular 1d    v = kcat [E] [S] / KM   
 
Formular 1e          v / [S} = slope = kcat [E} / KM 
 
Formular 1f    slope / [E] = kcat / KM 
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2.6. Methods for Aims 2-6 
 
2.6.1 Rats and diets 
Male Wistar rats (Charles River, Sulzfeld, Germany) weighing 365 ± 18 g were fed a standard 
diet containing 5 µg/g Vitamin K1 and water ad libitum. They were fed the diets shown in 
Figure 3 (all diets were from Altromin, Lage, Germany; Table 1). Diets a) - d) were applied 
for 4 weeks as a model for kidney failure with no overt vascular calcification, diets e) - h) as a 
model of severe calcification for 7 weeks. 7 weeks of adenine diet included a 2-week 
interphase on an adenine-free diet in week 5 and 6 for recovery of the animals. Vitamin K2 
diet contained 100 mg/kg MK4 (diets c, d, f) or 500 md/kg (diet g). Vitamin K1 was added to 
100 mg/kg (diet h) (Figure 8, Table 1). Organ harvesting was performed as described under 
2.5.2. 
 
 
Figure 8: Overview of the 8 different rat treatment groups. Seven weeks of treatment 
contained a 2-week interphase without adenine supplementation. 
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Table 1: Composition of diets and treatment duration 
 I diets composition [g/kg] 
Group Protein 
Energy 
Fat Fibre K1 [mg/kg] K2 [mg/kg] Adenine  Weeks [kcal/kg] 
a) 173.46 3720 50.3 0.06 5 - - 4 
b) 173.46 3720 50.3 0.06 5 - 7.5 4 
c) 173.46 3720 50.3 0.06 5 100 7.5 4 
d) 173.46 3720 50.3 0.06 5 100 - 4 
e) 25 3671 50.6 1.8 5 - 7.5 7 
f) 25 3671 50.6 1.8 5 100 7.5 7 
g) 25 3671 50.6 1.8 5 500 7.5 7 
h) 25 3671 50.6 1.8 100 - 7.5 7 
 
2.6.2 Blood pressure 
Blood pressure was measured in rats non-invasively by determining the tail blood volume 
with a volume recording sensor and an occlusion tail cuff on a Kent Scientific CODA system 
at weeks 0, 2, 4 and 7. Rats were placed into a restrainer and the warming plate was set on 
37°C. The Coda software was programmed on 5 cycles for acclimatisation and 10 cycles to 
obtain values. The systolic blood pressure is measured directly whereas the diastolic blood 
pressure is calculated by the software. Rats were trained before assessing values.  
 
2.6.3 Biochemistry 
Blood from rats was collected at after 0 and 4 weeks by tail vein puncture. Therefore, rats 
were placed into a restrainer and the tail was warmed with 38°C tap water. One of the 3 tail 
veins was punctured with a safety multifly canuele. At the end point (4 or 7 weeks), blood 
was collected by puncture of the left ventricle. Serum was obtained by spinning the blood 
sample tube at 2,000 x g for 10 min at 4°C. To collect the urine, animals were placed into 
metabolic cages for 24 h prior sacrifice (Institut für Versuchstierkunde, Aachen, Germany). 
Serum and urine parameters were measured by Vitros 250, Ortho Clinical Diagnostics, NY, 
USA clinical routine laboratory diagnostics (Institut für Versuchstierkunde, Aachen, 
Germany). Glomerular filatration rate (GFR) was calculated as followes: 
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Formula 2: 
creaserum
urinecreaurine
ct
Vc
mlGFR
*
*
min]/[ =
  
 
Ccreaurine: concentration of creatinine in urine [µmol/l] 
Vurine: Volume of urine [ml] 
t: time [min] 
ccreaserum: concentration of creatinine in serum [µmol/l] 
 
2.6.4 MGP ELISA 
MGP diagnostics were performed at VitaK BV, Maastricht, NL. 
Total uncarboxylated MGP was measured in serum by competitive ELISA by a monoclonal 
antibody (MGP sequence 35-49; VitaK BV, Maastricht, the Netherlands), as described 
previously (52).  
 
2.6.5 Enzyme activities 
Enzyme activites were tested using microsomes which were obtained as described under 
2.5.3. Each microsomal fraction was split to be tested in three enzyme activity assays, GGCX, 
VKOR and DT-diaphorase. Microsomes from aorta were only tested for GGCX activity due 
to the low amount of microsomal protein.  
  
2.6.5.1 GGCX activity assay 
GGCX assay was performed as described under 2.5.5. The amount of microsomal protein was 
250 µg and the reaction time was 30 min. For a selective influence on the γ-carboxylase 
activity, microsomes from healthy rats were first incubated with the uremic toxins urea (50 
mM, 500 mM), indoxylsulfate (250 µM, 500 µM) or p-cresol (100 µM) at room temperature 
for 30 min. Quantification of carboxylated FLEFLK-FITC was performed by rp-HPLC setup 
referring to 2.5.6. 
 
2.6.5.2 VKOR activity assay 
The VKOR activity was measured by conversion of vitamin K1 2, 3 epoxide (K1<O) to 
vitamin K1 (37). The reaction mixture, with a total volume of 200 µl contained 500 µg 
microsomal protein in sucrose buffer and 8 µl 5 mM K1<O. The reaction was started by the 
addition of 5 µl 200 mM DTT and stopped after 60 min incubation at 30°C in the dark by 500 
µl 0.05 M AgNO3 in isopropanol. The samples were centrifuged at 5,000 x g for 5 min. The 
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supernatant was taken for HPLC measurements. The HPLC system consisted of a pump (L-
7100), an autoinjector (L-7200), a column oven (L-7350), a UV- detector (L-7400) and an 
interface (D-7000) connected in line. Vitamin K1 was separated in reversed phase HPLC on a 
Max RP C12 column. Isocratic methanol at pH 5 (acidified with acetic acid) was used as a 
mobile phase with a continuous flow rate of 1 ml/min. The pressure limit was set at 350 bar. 
Vitamin K1 and vitamin K1>O were detected at 246 nm. Each run was recorded for 12 min. 
Vitamin K was quantified by external standards. For epoxidation, vitamin K1 was diluted in 
hexane and mixed with 0.5 M NaOH, 0.2 M Na2CO3 and 5% H2O2 for 12 h at 37°C in the 
dark. Vitamin K1>O quality was monitored by HPLC measurements.  
 
2.6.5.3 DT-diaphorase activity assay 
DT-diaphorase activity was analyzed in rat kidney and liver by the standard assay (53) with 
NADPH as electron donor and menadione as electron acceptor (Figure 9).  
 
 
Figure 9: Principle of the DT-diaphorase activity assay (from Prochaska 1987) (53). 
NADPH is generated by the conversion from glucose-6-phosphate to 6-phosphogluconate by 
glucose-6-phosphate dehydrogenase and is required as a cofactor for the DT-diaphorase 
(Quinone-reductase). Thereby, menadione is reduced to menadiol by the DT-diaphorase. 
MTT is reduced nonenzymatically by menadiol and forms a blue colour which is detected at 
610 nm (53). 
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A total volume of 150 ml reaction mixture contained 7.5 ml 0.5 M Tris-Cl (pH 7.4), 100 mg 
BSA, 1 ml 1.5% Tween-20, 0.1 ml 7.5 mM FAD, 1 ml 150 mM glucose-6-phosphate, 90 µl 
50 mM NADPH, 300 U yeast glucose-6-phosphate-dehydrogenase and 45 mg MTT. The 
assay was carried out in the presence and absence of 3 mM dicoumarol and 50 µM menadione 
with 250 µg microsomal protein (Figure 10).  
 
 
  
1 2 3 4 5 6 7 8 9 10 11 12 
a b1  S1 S2  S3   S1 S2  S3  S1  S2  S3      
b b2 S4  ...  ...  S4  ... ...  S4  ....  ....      
c b3                       
d ....                       
e 
                       
f 
                       
g 
                       
h 
   ...   S24    ... S24    ...  S24      
 
            
1-4: RM          
5-7: RD          
8-10: R          
 
Figure 10: Pipetting scheme of the 96-well plate for DT-diaphorase activity assay. 
b = nonenzymatic blank; S1-S24: sample number; RM = reaction mixture with menadione 
(timepoint t 5min); D: reaction mixture with menadione and dicoumarol (to determine the 
unspecific activity not inhibitable by dicoumarol); R: reaction mixture without menadione 
(representing timepoint t0) 
 
The reaction was stopped after 5 min at 20°C by 3 mM dicoumarol and 5 mM KCl. The DT-
diaphorase activity was calculated as the specific activity inhibited by dicoumarol. Reduced 
MTT as the formazan dye was detected at 610 nm on a Tecan sunrise microplate absorbance 
reader. To calculate the difference of reduced MTT extinction (δE) the arithmetic mean of the 
blank (B) is subtracted from each value first (i: sample number 1-24) and afterwards 
timepoint t0 from the extinction at timepoint 5 min (according to formula 3).  
 
Formula 3: δE = (Sit5min- B) – (Sit0 – B) 
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The extinction of the unspecific activity (SiD), also corrected for the mean of the blank, can 
be subtracted from the activity at timepoint t5 to calculate the extinction of the specific DT 
diaphorase activity (δEspec) (according to formula 4). 
 
Formula 4: δEspec = δE – (SiD - B) 
 
The concentration of the formazan dye reduced MTT (δc) can be calculated from the Beer 
Lambert law (formula 5). 
 
Formula 5: )*(][ d
E
Mc spec
ε
δ
=∂
 
 
ε = extinction coefficient of MTT at 610 nm = 11.3 mM/cm 
d = thickness of the sample = 0.7 cm 
 
The final result is depicted as specific activity per minute per g protein (formula 6). 
 
Formula 6: DT-diaphorase activity [mol/min/g] = (δc/5) * 4 
 
2.6.6 Calcium determination  
The extent of vascular and tissue calcium content was measured colorimetrically. Frozen 
samples weighing between 30-70 mg (aorta) or 100-250 mg (kidney, lung, heart) were 
lyophilised on a Christ Loc 1mALPHA 1-4 coupled with a vacuum hybrid pump RL 6 over 
night. Dried samples were weighed and incubated in 500 µl 10% formic acid over night to 
elute the calcium. For quantification of calcium deposition of VSMC, cells were washed twice 
with calcium-free PBS and incubated over night in 10% formic acid. 25 µl of each sample 
was measured twice in the Randox cresolphthalein assay. The working solution consisted of 
equal parts solution 1 (2-amino-2methyl-1-propan-1-ol 3.5mol/l, pH 10.7) and solution 2 
(containing the chromogen O-chresolphthalein 0.16 mmol/l). Calcium standards were 10, 5, 
2.5, 0.625 and 0 mg/dl. Absorption was measured at 550 nm on a Tecan sunrise microplate 
absorbance reader. Results were depicted in mg calcium per g dry tissue. 
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2.6.7 Histochemistry 
Kidney, lung, and thoracic aorta were fixed in 4% paraformaldehyde (Roti®-Histofix) for at 
least 24 h at room temperature. Dehydration of the samples was performed on an automated 
tissue processor (Slee tissue processor, Interdisziplinäres Zentrum für klinische Forschung 
IZKF, Aachen, Germany). Afterwards the samples were embedded in paraffin blocks. 4 µm 
thick sections were cut on a rotary microtome (Slee, Mainz, Germany). Microscope slides 
were incubated for 12 h at 37°C before staining. The base of the heart was embedded in tissue 
tek for cryosectioning. 10 µm thick sections were cut on a cryotome. 
Deparaffinization of the slices was performed by washing 3 x 5 min Xylol, 3 x 2 min 96% 
ethanol, 2 x 2 min 75% ethanol, 10 seconds in water.  
Localisation of the calcification was visualized by von Kossa staining (54). Therefore, 
deparaffined sections were immersed in 1% aqueous AgNO3 solution for 5 min. After 
washing, samples were incubated in a solution of 5% NaCO3 and 9.25% formalin for 1 min. 
After a second rinse, sections were developed using 5% sodiumthiosulfate for 5 min and 
counterstained in 0.1% safranin-O followed by a final rinse using tap water. Dehydration was 
performed by washing in 70% ethanol for 1 min, 95% ethanol for 1 min, 3 x 5 min in xylol. 
Stained slices were covered with Roti®-Histol and a cover glass. Quantification of von Kossa 
positive areas was performed with the help of imageJ software. Results are depicted in % 
positive area of total area. 
UcMGP was visualized in aortic tissues by incubation with the anti-GluMGP antibody (55), 
performed at the VitaK BV, Maastricht, NL. 
 
2.6.8 Real time PCR 
RNA was harvested from RNAlater® (Qiagen, Hilden, Germany) stabilized liver, abdominal 
aorta and heart using the Qiagen RNeasy mini kit. Purity and RNA concentration were 
analyzed with the Agilent RNA 6000 Nano Kit. 200 ng RNA was used for reverse 
transcriptase performed on a thermocycler in four steps: 1) 10 min at 25°C, 2) 3 min at 48°C, 
3) 5 min 95°C and 4) cool down.  
The qPCR Core Kit for SYBR Green I was applied for a two-step quantification on an Real-
Time PCR TagMan® system. The GGCX TaqMan® gene expression assay was performed 
from cDNA received from rat liver. GAPDH was used as a housekeeping gene. The following 
rat GAPDH primers were used:  
sense: ACAAGATGGTGAAGGTCGGT,  
antisense: AGAAGGCAGCCCTGGTAACC,   
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probe: CGGATTTGGCCGTATCGGACGC 3. 
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2.7. Methods for Aim 7 
 
2.7.1 Mice 
Two breeding pairs of Gas6-/- mice were kindly provided by Peter Carmeliet (University of 
Leuven, Belgium). Gas6-/- were backcrossed for more than 10 generations on a C57BL/ 
background, which served as a wildtype (WT) control.  
 
2.7.2 VSMC culture 
VSMC were isolated from the thoracic aorta of healthy adult C57BL/6 and Gas6-/- mice. 
Therefore, mice were killed with an overdose of isoflurane. The abdomen and the thorax were 
opened with sterile instruments. Organs were perfused with 10 ml cold PBS via puncture of 
the left ventricle. The iliac artery was incised to enable an out flow of blood and PBS. Liver, 
intestine, lung, kidney and spleen were removed to dissect the aorta. The thoracic aorta was 
cleaned from fat and surrounding tissue. After harvesting, aortas were washed twice with PBS 
and then incubated with 2 g/l collagenase and 1% elastase containing cell culture medium for 
1 h at 37°C. Aortas were cut into small pieces, washed twice with PBS and seed into T25 cell 
culture flasks. The smooth muscle cell basal medium was supplemented with fetal calf serum 
(0.05 ml/ml), epidermal growth factor (0.5 ng/ml), basic fibroblast growth factor (2 ng/ml), 
insulin (5 µg/ml) and finally 1% penicillin streptomycin and 0.1% gentamycin. Cell culture 
medium was changed twice each week. Cells were grown to 85% confluence untill passaging. 
Passages from 3-5 were used for calcification experiments in 12 well plates. Calcification 
medium contained 3 mM calcium phosphate or 10 nM warfarin plus 3 mM calcium 
phosphate. To induce calcification cells were cultured for 5 to 7 days. A negative control (d0) 
was included in each experiment to normalize the obtained values; calcium deposits were 
depicted as changes in %.  
 
2.7.3 Protein determination 
The adherent cells were diluted in 200 µl lysis buffer (0.8% Digitonin, 2 mM EDTA, pH 7.8) 
using a cell scraper. Protein content in VSMC was determinded as described under 2.5.4. 
 
2.7.4 TUNEL-assay 
Apoptosis measurements were performed with the Roche in situ cell death detection kit. All 
samples were fixed in methanol for 10 min at room temperature. VSMC were permeabilised 
by an aqueous solution of 0.1% sodium citrate and 0.1% Triton X for 2 min on ice. Cells were 
counterstained with DAPI (Vectashield®, containing 1.5 µg/ml DAPI). For positive control 
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cells were preincubated with DNase for 10 min at room temperature. For a negative control 
the terminal transferase was omitted. 
Stained slices were photographed on a Leica microscope at a 100 x magnification.  
Semiquantitative analysis of positive stained area was measured with ImageJ software. 
 
2.7.5 Mice: Surgery and diets 
Mice were divided into six groups: two healthy groups at the age of a) 8-10 weeks and b) 34-
36 weeks and four treatment groups: c) warfarin d) Uninephrectomy (UNiNx) and e) 
electrocautery (EC). For the surgical groups (UniNx and EC) the rodent chow (AB diets, 
Woerden, The Netherlands) was supplemented to 0.95% calcium and 1.65% phosphate. The 
warfarin chow contained 3 g/kg. The warfarin diet or surgery was started at the age of 8-10 
weeks and the diets were continued for 8 weeks. UniNx was performed at the age of 8 weeks. 
All surgery was performed under Ketamin/ Rompun (0.2 ml 10% Ketamin, 0.25 ml 2% 
Xylazin, 0.25% NaCl) anaesthesia. Anaesthesia was injected intraperitoneally at a dosage of 2 
µl/g body weight 10 min earlier. The depth of anaesthesia was checked by a gentle skin pinch. 
The surgery was started after desinfection with an incision on the left flank. The kidney was 
exposed and after ligation of the ureter, renal artery and vein with non resorbable silk- 
removed. After one week of recovery, high phosphate diet was initiated (Figure 11). For more 
severe kidney damage, electrocautery of the right kidney at the age of 8 weeks plus 
uninephrectomy of the left kidney 2 weeks later was performed. For electrocautery, punctual 
lesions were set on the renal cortex with a 2 mm diameter electrocoagulation ball tip over all 
areas of the kidney. The 1 mm deep punctuate lesions were spaced 2 mm apart (56) (Figure 
12). After 2 weeks, the contralateral kidney was removed and after one additional week the 
high phosphate diet was started (Figure 11). In all experiments female animals were used, 
except in ageing mice where both gender were analyzed. Tissue was harvested as described 
under 2.6. 
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Figure 11: Experimental design of the in vivo mouse experiments. 
 
 
 
Figure 12: Electrocauterisation of the right kidney; punctuate lesions are set on the renal 
cortex. 
 
2.7.6 Genotyping 
DNA was isolated from snap frozen WT and Gas6-/- mice liver tissues from each treatment 
group at different timepoints throughout the breeding time of the experiment. The liver was 
homogenized in a ball mill in ALT lysis buffer at 20 Hz for 2 minutes. Protein was digested 
by incubation for 45 min at 56°C with proteinase K. Further DNA isolation was performed 
with the Qiagen QIAmp DNA Mini Kit. Ready to go PCR beads were used for cDNA 
synthesis. DNA was amplified on a thermocycler (step 1) 94°C 2 min, step 2) 94°C 30 sec, 
Gas6-/- 
WT Warfarin Diet 
Warfarin Diet 
UniNx High Phosphate Diet 
UniNx High Phosphate Diet 
UniNx High Phosphate Diet EC 
UniNx High Phosphate Diet EC 
 0    1           2                  3                                     8                            10                12 Weeks 
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step 3) 58°C 30 sec, step 4) 72°C 30 sec, step 5) go to step 2 for 34 times, step 6) 72°C 10 
min, step 7) hold). Primer sequences made by Invitrogen (Invitrogen, CA, USA) were:  
Mgas6 1S: 5' GAG-TGC-CGT-GAT-TCT-GGT-C 3';  
Mgas6 2A: 5' CCA-CTA-AGG-AAA-CAA-TAA-CTG 3'.   
The PCR product was seperated on a 1% agarose gel (2 g agarose, 200 mL TAE buffer) at 
130 V in TAE buffer (50 x TAE: 18.61 g/l (0.05 M) EDTA Na2 2 H2O; 60.05 g/l (1 M) acetic 
acid and 242.28 g/l (2 M) TRIS) for 45 min. Bands were visualized with ethidium bromide 
and identified with the 1 kb DNA ladder Fermentas GeneRuler™. 
 
2.7.7 Biochemistry 
Blood from mice was collected by puncture of the left ventricle during sacrifice and collected 
in a serum tube. Serum and urine diagnositics were performed as described under 2.6.3. 
 
2.7.8 Calcium determination 
VSMC were washed twice with calcium free PBS and each well was incubated 10% formic 
acid over night. Quantification of VSMC and tissue calcium content (aorta, heart, kidney) was 
performed as described under 2.6.6. 
 
2.7.9 Echocardiography 
Transthoracic echocardiography was performed on the Visulasonics high resolution micro-
imaging system Vevo 770 using the RMV 704 scanhead. Therefore, mice were anaesthetised 
with isoflurane and placed on a warming plate at 37°C. The thorax was fully depilated. 
Breathing and heart frequency were monitored, continuously. A long axis view loop was 
recorded in the brightness mode (B-mode). Left ventricular (LV) mass was calculated in the 
motion mode (M-mode) in the long axis view (Figure 13) from the Devereux formula:  
 
Formula 7: LVM [mg] = 1.04*[(LVID+LVPW+LVSW)3-LVID3] 
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Figure 13: M-mode of the long axis view. The left ventricular inner diameter is measured in 
the systole (LVIDs) and the diastole (LVIDd), as well as the thickness of the septal wall (SW) 
and the left ventricular posterior wall in the diastole (LVPWd). 
 
The short axis view is obtained by a 90 degree rotation of the scanhead (RMV 704) in the B-
mode. Ejection fraction (EF) as an index for global left ventricular systolic function was 
measured by the Simpson`s method. Therefore, the heart was divided into 4 equal sections 
along the longitudinal axis (Simpson 1-4) and for each a short axis view loop was taken. The 
endocardial area was measured in each picture of the short axis view in the systole and in the 
diastole to obtain the end diastolic (EDV) and end systolic volumes (ESV) (Figure 14).  
 
Formula 8: 100*[%] EDV
SVEF =
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Figure 14: Short axis view of the diastole to measure the endocardial area (here Simpson 3) of 
the left ventricle. 
 
Stroke volume (SV) was estimated as the difference between the LV end-systolic and end-
diastolic volumes as follows:  
 
Formula 9: ESVEDVµLSV −=][   
 
Pulse-wave velocity (PWV) in the right common carotid artery was measured using the 
transit-time method in a two-dimensional mode. In the carotid artery, the proximal pulse wave 
signal was obtained 1 mm behind the origin of the subclavian artery, the distal signal 1 mm 
before the carotid bifurcation (Figure 15). The transit time was found by subtracting the distal 
arrival time between the R-wave peak and the foot of velocity upstroke from the similarly 
determined proximal arrival time: 
 
Formula 10 )(]/[ proxdist PtPt
d
msmmPWV
−
∆
=
 
 
Pt is the time point of the proximal or distal pulse wave signal and ∆d is the distance between 
the two measurements.  
endocardial 
area 
right ventricle left ventricle 
papillary 
muscles 
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Figure 15: Assessment of the PVW in the arteria carotis communis. The doppler mode for the 
distal point is placed 1 mm before the bifurcation (small box) at an angel of 45 degrees. Then, 
the time between the ECG and the pulse wave can be measured (big box). 
 
2.7.8 Histochemistry 
Von Kossa staining was performed as described under 2.6.7. 
Sirius red staining for collagen was performed in cryo sections from heart tissues from 
warfarin treated mice. Samples were incubated in 5 w/v % Sirius red for one hour in picric 
acid at room temperature. Afterwards the samples were washed twice in acidified ethanol (70 
v/v %; pH 3.5).  
 
2.7.9 Real time PCR 
Real time PCR was performed as described under 2.6.8. 
Quantification of MGP gene expression was performed from cDNA from Gas6-/- and WT 
mice aortas with external standards for MGP (8.8 * 106 – 8.8 * 10) and GAPDH (6.4 * 106 – 
6.4 * 10).  
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MGP probe was AGAGTCCAGGAACGCAACAAGCCTGC, 
sense primer GCAGAGGTGGCGAGCTAAAG and 
antisense primer AGCGCTCACACAGCTTGTAGTC (57).  
Corresponding murine GAPDH probe was AAGGCCGAGAATGGGAAGCTTGTCATC, 
sense primer AAGTGGTGATGGGCTTCCC and 
antisense primer GGCAAATTCAACGGCACAGT. 
 
2.8 Statistical analysis 
The difference between the treatment groups was assessed by one-way ANOVA followed by 
Tukey`s multiple comparison test. Equal variances were tested with Bartlett`s method. 
D`Agostino and Pearson normality test was performed to check for Gaussian distribution. 
Statistical significance was defined as p < 0.05. Linear correlations were calculated in Origin 
Pro8 software. 
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3. RESULTS 
 
3.1 Results for aim 1  
 
3.1.1 Peptide Design 
The properties of the designed hexapeptide FLEFLK-FITC was tested on rp-HPLC coupled 
with UV-detection and in LC/MS/MS measurements before and after in vitro carboxylation. 
 
3.1.1.1 Detection of the uncarboxylated FLEFLK-FITC 
The lipophilic FLEFLK-FITC was detected after 19.44 min rp-HPLC (Figure 16) and 19.55 
min in MS measurements (Figure 17).  
 
 
Figure 16: Rp-HPLC chromatogram of the purified reaction mixture at t=0. FLEFLK-FITC 
peak was detected after a retention time of 19.44 min. 
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Figure 17: MS chromatogram of unmodified FLEFLK-FITC peptide solution with a distinct peak at 19.55 min (box).  
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There were no differences between the HPLC and MS patterns of the pure, diluted Glu-
peptide and the purified reaction mixture at t = 0. The detection limit of uncarboxylated 
FLEFLK-FTIC in HPLC measurements was <10 ng/ml. There was a linear correlation of 
FLELFK-FITC between 10 ng -5 µg (R2 = 0.99) (Figure 18).  
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Figure 18: Linear correlation of the peak area and the amount of uncarboxylated FLEFLK-
FITC. Used concentrations were 10 ng, 25 ng, 50 ng, 100 ng, 250 ng, 500 ng, 1 µg, 2.5 µg 
and 5 µg.  
 
The MS pattern was in accordance with the manufacturer’s analysis with distinct peaks at 
390, 594, 926 and 1,186 m/z (Figure 19), the last matching the stated peak of highest mass 
corresponding to the molecular mass of the intact FITC-labelled peptide (Table 2). 
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Figure 19: MS spectrum of FLELFK-FITC at 19.55 min
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The 390 m/z fragment is expected to be FITC and the 594 m/z fragment could not be further 
identified. The purity of the peptide in reversed phase-HPLC analysis was 91%. The 
remaining 9% mainly include peptide fragments, salt and water, as supplied by the 
manufacturer. 
 
3.1.1.2 Characterization of the carboxylated FLEFLK-FITC 
After running the carboxylase assay on the FLEFLK-FITC probe peptide, the lipophilic, 
hydrophobic FLGlaFLK-FITC product peptide showed a shorter retention time in reversed 
phase HPLC and was detected at 15.66 min in HPLC (Figure 20) and at 15.76 in MS 
measurements (Figure 21). Here, the in vitro reaction time was increased from 30 to 60 
minutes in order to increase the amount of carboxylated peptide. In MS distinct peaks appear 
at 394, 438, 523, 577, 582 and 1,229 m/z (Figure 22, Table 2). The carboxylated peptide was 
stable over 24 h at 4°C in the dark.  
 
 
 
Figure 20: HPLC chromatogram of the reaction mixture at t = 30 min. A distinct peak appears 
at 15.66 min representing the carboxylated FLEFLK-FITC peptide as identified by LC/ESI-
MS; a smaller peak at 19.24 min represents the uncarboxylated peptide (referring to figure 
16). 
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Figure 21: LC/MS chromatogram of the carboxylated FLELFK-FITC at in vitro reaction time t = 60, a distinct peak appears at 15.76 min (box).
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Figure 22: Mass spectrum of the carboxylated peptide at run time 15.76 min (referring to box figure 21). Asterisks indicate peaks representing 
carboxylated peptides (referring to table 2). 
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Table 2: Molecular weights of MS fragments 
Fragments   
intact peptides 
calculated MW 
[g/mol] 
measured MW 
[g/mol] 
Phe-Leu-Gla-Phe-Leu-Lys-FITC 1229.4 1229.8*** 
Phe-Leu-Glu-Phe-Leu-Lys-FITC 1185.3 1186.1 
 MS fragments   
Glu-Phe-Leu-Lys-FITC 924.0 925.8 
Phe-Leu-Glu-Phe-Leu-Lys 795.0 796.8 
Phe-Leu-Glu-Phe-Leu 650.8 649.8 
Gla-Phe-Leu-Lys 577.6 576.7* 
Phe-Leu-Glu-Phe 537.6 536.3 
Phe-Leu-Gla-Phe 581.6 581.5** 
Gla-Phe-Leu 433.5 437.8 
Phe-Leu-Lys 391.5 393.8 
FITC 390.4 390.3 
List of unmodified FLEFLK-FITC and carboxylated FLEFLK-FITC with possible cleaved 
peptides generated by MS electrospray ionisation resembling positively charged fragments. 
Asterisks indicate carboxylated peptides corresponding to figure 22. 
 
3.1.2 GGCX activity method 
The GGCX activity was determined in microsomal preparations (9-21 mg/ml total protein) 
from kidney and liver tissues of healthy male rats fed a standard diet. The enzyme reaction 
was linear between 15 and 120 min (R2 = 0.98) (Figure 23).  
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Figure 23: Linear correlation between in vitro reaction time and formed FLGluFLK-FITC (R2 
= 0.98). 
 
A variation in the microsomal protein content resulted in a linear slope (R2 = 0.99) between 
50 and 750 µg microsomal protein (Figure 24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Linear correlation between the amount of microsomal protein and GGCX activity.  
 
A variation in substrate however did not follow Michaelis Menten kinetics (data not shown). 
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The GGCX activity in liver microsomes was 481 ± 245 nmol/min/g protein and in kidney 
microsomes 412 ± 42 nmol/min/g protein. Treatment with NEM reduced the activity to 17.6 ± 
10.7 in liver samples and 62.0 ± 49.0 nmol/min/g microsomal protein in kidneys (Figure 25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: GGCX activity in rat liver and kidney without and with specific NEM inhibition (n 
= 7 and n = 3, respectively). 
 
3.1.3 14CO2 incorporation 
 
FLELFK-FITC showed incorporation of 14CO2 during in vitro γ-carboxylation with a linear 
increase with increasing peptide concentrations from 0.3 -2.2 µM (Figure 26). 
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Figure 26: 14CO2 incorporation of FLEFLK-FITC in the GGCX assay 
 
Based on the slope of the curve, the calculated kcat/Km value for FLEFLK-FITC was 3.5 fold 
higher than reported for FLEEL (5068 vs. 1413 h-1mM-1) (58). Using the radioactive assay, 
increasing amounts of acetonitrile inhibit the GGCX activity (Figure 27). 
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Figure 27: Effect of acetonitrile on GGCX activity.
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3.2 Results for aims 2-6 
 
3.2.1 Blood pressure  
Systolic blood pressure levels measured in rats at the beginning and the end of each treatment 
period were unchanged in all groups (Figure 28). No changes were observed in diastolic 
blood pressure (for group e, CKD from 74 ± 5 mmHg at week 0 to 85 ± 10 mmHg at week 
7). 
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Figure 28: Time course of systolic blood pressure levels in CKD rats compared to healthy 
controls (group a); increase in CKD group (group e) is not significant. 
 
3.2.2 Biochemistry  
After 4 weeks of adenine treatment (group b), we observed a 6-fold increase in serum 
creatinine (Figure 29 and Table 3) and a 7-fold increase in serum urea (Table 3). Adenine diet 
combined with low protein diet led to slightly higher creatinine (Figure 29) and phosphate 
(Figure 30) levels in serum after 4 weeks, compared to adenine diet with normal protein.  
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Figure 29: Creatinine levels in rat serum after 4 weeks of treatment. Increase was significant 
in all adenine fed groups. 
*: significant to group a) healthy control; #: significant to group b) adenine treatment. 
 
Figure 30: Phosphate in rat serum after 4 weeks of treatment. The low protein diet lead to 
higher levels even after 4 weeks of diet compared to normal protein diet. 
*: significant to group a) healthy control; #: significant to group b) adenine; +: significant to 
group e) adenine with low protein. 
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After 7 weeks of treatment, serum phosphate levels in the vitamin K2 high dose group (500 
mg/kg + adenine) were significantly lower than in CKD (after 7 weeks of adenine based on 
low protein, Table 3). Serum calcium was unchanged in all groups at every time point (Table 
3). 
 
Table 3: Final biochemical results in rat serum 
Serum 
Group 
Urea Creatinine  Calcium Phosphate 
[mmol/L] [µmol/L] [mmol/L] [mmol/L] 
a) 6.23 (± 1.67)# 32.40 (± 3.08)# 2.46 (± 0.11) 2.08 (± 0.18)# 
b) 29.16 (± 7.16)* 173.60 (± 63.23)* 2.45 (± 0.16) 4.16 (± 0.94)* 
c) 32.03 (± 7.36)* 133.17 (± 29.09)* 2.51 (± 0.21) 3.23 (± 0.78)* # 
d) 4.09 (± 0.98)# 29.00 (± 3.20)# 2.57 (± 0.07) 2.42 (± 0.24)# 
e) 36.37 (± 17.63)* 388.44 (± 115.43)* 2,53 (± 0.30) 6.57 (± 1.79)* 
f) 31.30 (± 9.60)* 356.83 (± 92.50)* 2.62 (± 0.18) 6.06 (± 1.15)* 
g) 34.42 (± 28.26)* 317.71 (± 93.48)* 2.66 (± 0.40) 5.22 (± 2.02)* 
h) 42.81 (± 30.80)* 429.71 (± 120.01)* 2.94 (± 0.57) 6.75 (± 1.75)* 
*: significant to group a) healthy control; # significant to group b) CKD 4 weeks  
 
Renal creatinine excretion and GFR (Figure 31) were reduced in all adenine fed groups 
(Table 4).  
 
Table 4: Final biochemical results in rat 24 h urine 
Urine Creatinine  Protein  Phosphate 
Group [µmol/L] [mg/dL]  [mmol/L] 
a) 9964 (± 8889.5)#+ 26.71 (± 4.39) 58.79 (± 69.45) 
b)  1792.3 (±232.7)* 38.5 (±6.22) 15.44 (± 6.03) 
c)  1327.2 (±319.9)* 38.33  (±8.91) 14.33 (± 5.34) 
d) 10433.6 (±6612.1)*#+ 25 (±2.74)  59.83 (± 38.23) 
e) 2367.3 (±488.4)* 40.28 (± 13.77) 21.82 (± 2.96) 
f) 1817.4 (±368.5)* 45.33  (±33) 17.92 (± 4.47) 
g) 2099.3 (±1001.5)* 29.66 (±8.09) 18.78 (± 12.46)  
h) 2222.7 (±585.9)* 37.3 (±11.1)  17.19 (± 3.94) 
*: significant to group a) healthy control; # significant to group b) CKD 4 weeks; + significant 
to group e) CKD 7 weeks 
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Figure 31: Glomerular Filtration rate (GFR) is reduced in adenine fed rats I) after 4 weeks; II) 
after 7 weeks of treatment; *: significant to group a) healthy control; #: significant to group b) 
4 weeks of adenine. 
 
Significantly higher levels of ucMGP were measured in the 4-week CKD group b (Figure 32 
I). After 7 weeks, no significant differences in ucMGP levels were detected (Figure 32 II). 
 
 
Figure 32: UcMGP measured in rat serum a) after 4 weeks; b) after 7 weeks of treatment. The 
only significant increase is seen after 4 weeks of adenine diet. 
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3.2.3 Enzyme acticvities 
3.2.3.1 GGCX activity 
Compared to group a) (healthy non-CKD controls) GGCX was significantly less active in the 
uremic groups (b and c) in kidney (Figure 33I) and liver tissue after 4 weeks of adenine 
treatment (Figure 33III). After 7 weeks of adenine treatment, the activity was even further 
reduced in kidney tissues (Figure 33II). A high dosage of vitamin K2 or vitamin K1 increased 
GGCX activity in kidney tissue after 7 weeks back to baseline values and was even higher in 
liver tissue (Figures 33II, 33IV). Reduced GGCX activity was also found in aortic tissue after 
7 weeks (Figure 34) and exceeded values from healthy and untreated animals (160.7 ± 54.71 
nmol/g/min) by high intake of either vitamin K1 or K2. No difference due to vitamin K 
treatment was detected in aortic tissue after 4 weeks of adenine diet.  
 
Figure 33: GGCX activity (mean ± SD) in kidneys [I after 4 weeks, II after 7 weeks] and 
liver [III after 4 weeks, IV after 7 weeks of adenine diet].  
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Figure 34: GGCX activity in aortas after 7 weeks (mean ± SD) of adenine diet. 
 
Urea is supposed to modify molecular enzyme activities by carbamylation of lysine residues. 
In vitro co-incubation of 50 mM urea with microsomes from healthy animals did not lead to a 
reduction of GGCX activity (Figure 35).  
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Figure 35: In vitro incubation with 50 mM urea prior GGCX activity assay, microsomes were 
isolated from healthy aorta, kidney and liver. No influence was seen by supplementation of 
urea to the carboxylation mixture. 
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Also no changes in enzyme activity were found after in vitro incubation with p-cresol or 
indoxylsulfate (data not shown).  
 
3.2.3.2 VKOR activity 
To determine VKOR activity, the measurement of vitamin K in rp-HPLC was established, 
first. Vitamin K1 was eluted in the rp-HPLC setup at 8.7 min (Figure 36) with a detection 
limit < 0.5 ng/ml. Between 0.5 - 50 ng/ml the correlation between the area under the curve 
and the injected vitamin K1 concentration was linear with R2 = 0.99 (Figure 37). 
 
 
Figure 36: Vitamin K1 peak at 8.7 min in rp-HPLC setup; Amount of Vitamin K1: 50 ng/mL, 
Injection volume 50 µl. 
 
Chapter 3.2_____________________________________________________________  
 
 71
0 10 20 30 40 50 60
0
2000000
4000000
6000000
concentration K1 [ng/mL]
a
re
a
 
Figure 37: Linear correlation of Vitamin K1 and area under the curve in rp-HPLC setup; used 
concentrations were: 0.5, 1, 2.5, 5, 10, 20, 30 50 ng/ml. 
 
K1>O was eluted at 6.3 min with a detection limit < 10 ng/ml. Vitamin K1>O was stable for 
at least 6 months at -20°C (99% purity) measured by rp-HPLC. VKOR activity did not differ 
significantly between the groups and ranged between 0.6 and 2.6 µmol/g/min in kidney tissue 
and from 0.5 and 7.1 µmol/g/min in liver tissue (Table 5).  
 
Table 5: VKOR activity in rat kidney and liver (mean ± SD)  
 VKOR [µmol/g/min] 
group kidney liver 
a) 1.43 (± 0.82) 2.05 (± 1.98) 
b) 1.52 (± 0.40) 6.91 (± 9.97) 
c) 1.28 (± 0.78) 4.81 (± 8.39) 
d) 2.10  (± 0.72) 7.14 (± 10.18) 
e) 0.57  (± 0.11) 2.01 (± 0.25) 
f) 2.55  (± 0.99) 0.5 (± 0.32) 
g) 1.66  (± 0.84) 2.5 (± 2.63) 
h) 2.09  (± 0.74) 1.77 (± 1.40) 
 
3.2.3.3 DT–diaphorase activity 
DT-diaphorase activity was significantly higher in kidneys and liver in the 4-week CKD 
model (group b) (3.6 fold and 2.7 fold, respectively, Figure 38I and 38III). After 7 weeks of 
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additional vitamin K1 or K2 treatment in the severe calcification groups (groups g, h), DT-
diaphorase activity was reduced to baseline values in the liver (Figure 38IV). 
 
 
Figure 38: DT-diaphorase activity (mean ± SD) in kidneys [I after 4 weeks, II after 7 weeks 
of adenine diet] and liver [III after 4 weeks, IV after 7 weeks of adenine diet]. 
 
3.2.4 Calcium measurements  
After 4 weeks of treatment, the aortic calcium content was significantly increased only in the 
adenine groups b) compared to healthy controls (groups a, d) (Figure 39I). After 7 weeks of 
adenine treatment, the aortic calcium content was significantly higher than in healthy controls 
(groups a and d) and after 4 weeks of adenine (group b) (Figure 39II). Aortic calcium 
deposition was reduced in the adenine plus high vitamin K groups (g, h) compared to CKD 
controls (group e) (Figure 39II). The cardiac calcium content increased after 7 weeks of 
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adenine treatment (group e CKD) and high dose vitamin K treatment significantly reduced 
cardiac calcium content (groups g, h) as compared to CKD (Figure 39IV). Kidney calcium 
content was significantly elevated after 4 weeks of adenine treatment without vitamin K 
substitution (group b CKD) as well as after 7 weeks with low dose vitamin K treatment 
(group f; 100 mg/kg, Figure 39V and 39VI). Kidney calcium content was significantly 
reduced by high dose vitamin K2 (group g) supplementation or K1 (group f) (Figure 39VI). In 
pulmonary tissue, no significant changes in the calcium content were detected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3.2_____________________________________________________________  
 
 74
 
 
 Figure 39: Calcium content in tissues (mean ± SD); Calcium content in aorta [I after 4 
weeks; II after 7 weeks], heart [III after 4 weeks; IV after 7 weeks] and kidney [V after 4 
weeks; V after 7 weeks]. 
 
3.2.5 Histochemistry 
Quantification of calcified areas by von Kossa staining confirmed the results obtained by 
chemical calcium assessment, but none of the differences reached statistical significance. 
Overt vascular calcification was present after 7 weeks of adenine, and in von Kossa-stained 
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aortic specimens, the calcified area increased on average 7.7-fold compared to the status at 4 
weeks (Figures 40).  
 
Figure 40: Quantification of von Kossa staining in rat aortic tissue (mean ± SD) after adenine 
diet.  
 
Vascular media calcification co-localized with positive staining for ucMGP (Figure 41). 
Healthy animals did not show aortic calcification or positive staining for ucMGP by 
histology. 
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Figure 41: Von Kossa and ucMGP staining in rat aortic tissue (100 x): early calcification after 4 weeks of adenine (group b) and overt calcification 
after 7 weeks of adenine diet (group e). UcMGP positive staining (red colour) occurs at calcification sites (group e). 
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3.2.6 GGCX gene expression 
The GGCX gene expression assessed by RT-PCR in liver tissue was similar in all groups after 
4 weeks of adenine diet (Figure 42). 
 
Figure 42: Relative expression of GGCX in rat liver. No changes were seen after 4 weeks of 
treatment. 
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3.3 Results for aim 7 
 
In order to assess the role of Gas6 protein in vascular calcification processes, in vitro and in 
vivo models were used.  
 
3.3.1 VSMC 
In vitro, VSMC of WT and Gas-/- mice were challenged by supplementation of calcium and 
phosphate or warfarin on top. Using calcification medium the deposition of calcium in VSMC 
increased over time and after 120 h calcium content was 4-fold increased in WT and only 1.4 
times in Gas6-/- (Figure 43a); however this difference was not significant. After 168 h of 
incubation the calcium load of VSMC increased further with no significant difference 
between VSMC from Gas-/- and from WT mice. (Figure 43a).  
Warfarin treatment led to a significant increase of calcium deposition in WT cells after 120 h 
(WT to 1.40% ± 0.77%; WT t120: 5.52% ± 5.17%). Again, there was no significant difference 
in calcium load between Gas6-/- and WT-derived VSMC (data not shown).  
The rate of VSMC apoptosis in calcification medium ± warfarin supplementation increased 
over the time course; however the rate of apoptosis was not increased in Gas6-/- compared to 
WT VSMC (Figures 43b and 44).  
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Figure 43: a) Ca2+ deposition in VSMC derived from Gas6-/- and WT mice after 168 hours (h) 
of exposure to phosphate and calcium enriched cell culture medium. b) TUNEL positive 
VSMC of Gas6-/- and WT mice after exposure to phosphate and calcium enriched cell culture 
medium.
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Figure 44: TUNEL and DAPI staining in VSMC from WT mice after 0 and 5 days of calcification medium plus warfarin 
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3.3.2 In vivo calcification models 
In vivo animals of Gas6-/- were compared to WT mice. 
All mice survived warfarin treatment without weight loss. In both strains 16% died after 
UniNx surgery. Somehow in the EC group all WT mice survived the surgical protocol. But 
only 40% of Gas6-/- mice survived to the end of the experiment (Figure 45).   
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Figure 45: Kaplan-Meier curve after electrocautery surgery in WT and Gas6-/- mice. 
 
3.3.2.1 Genotyping 
Only DNA isolated from snap frozen WT and not Gas6-/- mice showed a distinct band at 500 
bp (Figure 46).  
 
Figure 46: DNA gel for Gas6 gene; line 1: page ruler DNA ladder with a bright reference 
band at 1000 bp; lines 2-8 DNA isolated from Gas6-/-; lines 9-15 DNA from WT mice,  
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3.3.2.2 Biochemistry 
In healthy, untreated mice at the age of 8 weeks, alkaline phosphatase serum levels were 
lower in Gas6-/- than in WT mice (Table 6). Serum protein levels were higher in older mice 
and significantly lower in old Gas6-/- compared to old WT mice (Table 6). 
 
Table 6: Baseline biochemical characteristics of healthy WT and Gas6-/- mice at different ages 
(Mean ± SD).  
  8-12 weeks old, healthy 34-36 weeks old, healthy 
Parameter C57BL\6 Gas6-/- C57BL\6 Gas6-/- 
Body weight [g] 20.2 ± 0.7 18.6 ± 1.6 30.06 ± 6.36  26.41 ± 4.19 
haematology         
Urea [mmol/l] 13.26 ± 0.25   11.55 ± 1.92 6.65 ± 0.97  6.06 ± 0.91  
Creatinine [µmol/l] 20.67 ± 0.58 24.50 ± 8.60 18.00 ± 5.89  26.25 ± 16.73  
Calcium [mmol/l] 2.56 ± 0.09 2.23 ± 0.08 2.39 ± 0.13 2.39 ± 0.09  
Phosphate [mmol/l] 2.46 ± 0.11 3.05 ± 0.82 2.88 ± 0.45  2.85 ± 0.34 
Protein [g/dl] 5.00 ± 0.00 4.90 ± 0.15 6.00 ± 0.42  5.50 ± 0.26 *  
Alkal. phosphatase [U/l] 332.67 ± 8.62 255.63 ± 34.55 * 142 ± 53.52  207.33 ± 69.45  
* p < 0.05; to corresponding WT group 
 
Serum protein levels increased significantly in both mouse strains after warfarin diet (Table 
7). Serum creatinine levels increased after UniNx surgery compared to healthy animals in 
Gas6-/- and WT mice (+ 46% in WT and + 24% in Gas6-/-, respectively) (Table 7). Serum 
calcium, phosphate and creatinine levels were significantly increased in WT and Gas6-/- mice 
after electrocautery compared to the corresponding healthy controls (Table 7). 
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Table 7: Biochemical heamatology and 24 h urine characteristics of wildtype and Gas6-/- mice after different treatments 
Parameter C57BL\6 Gas6-/- 
model Warfarin UniNx Electrocautery Warfarin UniNx Electrocautery 
body weight [g] 22.95 ± 1.57  24.42 ± 2.17 ‡ 22.35 ± 1.64 18.90 ± 1.66  19.06 ± 3.19 * 18.45± 3.05  
haematology             
Urea [mmol/l] 6.27 ± 0.63 10.26 ± 3.58 10.58 ± 1.62 6.43 ± 1.29 10.25 ± 2.56 17.1 ± 11.58  
Creatinine [µmol/l] 22.00 ± 1.67 25.11 ± 2.37  30.28 ± 3.74  23.67 ± 6.32 29.91 ± 14.12 30.29 ± 3.86  
Calcium [mmol/l] 2.58 ± 0.09 2.50 ±  0.12 2.73 ± 0.14 ‡ 2.67 ± 0.17 2.50 ±  0.12 2.84 ± 0.27 ‡ 
Phosphate [mmol/l] 2.84 ± 0.22  2.78 ± 0.29 2.90 ± 0.30  3.68 ± 0.60  3.47 ± 0.89  3.91 ± 0.68   
Protein [g/dl] 6.58 ± 0.38 ‡ 5.74 ± 0.74  5.47 ± 0.49   6.03 ± 0.32 ‡ 5.70 ± 0.31 ‡ 5.41 ± 0.55   
Alkal. phosphatase [U/l] 205 ± 26.59 ‡ 173.11 ± 64.73 ‡ 166.33 ± 35.90 ‡ 227.67 ± 45.87  201.18 ± 63.97 187.00 ± 74.08  
24h urine             
GFR [µl/min] 76.88 ± 36.88  55.17 ± 32.44  41.71 ± 21.31  56.63 ± 32.83  41.65  ± 28.06 40.38 ± 13.00 
Protein [mg/dl] 25.88 ± 17.23  12.83 ± 4.58 ‡ 6.66 ± 1.86 ‡ 14.00 ± 4.93  9.50 ± 5.99 ‡ 17.67 ± 4.16  
Creatinine [µmol/l] 2071 ± 2005  3853 ± 2520  3062 ± 1133 4283 ± 3853  2175 ± 667  914 ± 179  
* p < 0.05; to corresponding WT group; ‡ p < 0.05 to healthy control group
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3.3.2.3. Calcium measurements 
As ageing could be related to vascular pathology, older mice (at the age of 34 - 36 weeks) 
were tested for a possible different development of spontaneous vascular calcification. 
Calcium content was not significantly different in both old Gas6-/- and old WT mice (Figure 
47). Von Kossa staining revealed only minor calcifications in both groups without significant 
differences (Figure 48).  
 
Warfarin administration was used to induce calcification by blocking the posttranslational 
activation of MGP and potentially Gas6. After warfarin diet, no significant differences in soft 
tissue calcification between WT and Gas6-/- mice were detected (Figure 47a), except for a 
reduced cardiac calcium content in Gas-/- mice after 8 weeks of warfarin (Figure 47b).  
 
UniNx (plus high phosphate diet) was used to initiate kidney damage. Spotty calcifications 
were present in the aorta (Figure 49a) and in cardiac tissue, however without obvious 
differences between Gas6-/- and WT mice. Within the heart calcifications were mainly located 
at the valves (Figure 49b). The most prominent calcification was found in kidney tissues in 
both strains, spreading throughout all structures with accumulation at the renal cortex (Figure 
49c). Again, there was no significant difference between the models with respect to tissue 
calcium content (Figure 47c).  
 
Electrocautery of the contralateral kidney was used in addition to UniNx (plus high phosphate 
diet) to further increase the extent of kidney damage. Calcium content in aortas and hearts of 
Gas6-/- mice was slightly higher than in WT, however without a significant difference (Figure 
47). Calcification spots were found in a similar pattern than after UniNx in all kidney 
structures in both, WT and Gas6-/- mice. 
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Figure 47: Ca2+ content in soft tissues after warfarin diet, UniNx, EC or in healthy aging WT 
(C57BL/6) and Gas6-/- mice. a) aorta, b) heart, c) kidney. UniNx (Uninephrectomy), EC 
(Electrocautery). 
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Figure 48: Von Kossa staining of aorta, heart and kidney in old WT compared to Gas6-/- mice (100 x). 
 
a) Aorta                         b) Heart                           c) Kidney  
Gas6-/- 
 
 
 
 
 
 
 
 
 
 
 
WT 
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Figure 49: Von Kossa staining of aorta, heart and kidney after uninephrectomy in WT compared to Gas6-/- mice (100 x). 
 
a) Aorta, UniNx                            b) Heart, UniNx                    c) Kidney, UniNx 
Gas6-/- 
 
 
 
 
 
 
 
 
 
 
 
WT 
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3.3.2.4 Echocardiography 
The cardiac function of healthy young and ageing, warfarin treated, uninephrectomized and 
electrocoauterized mice was investigated. Echocardiography revealed a higher LV mass in 
healthy Gas6-/- compared to healthy WT mice at the age of 8 weeks (Table 8). After UniNx, 
EF in was significantly higher in Gas6-/- compared to WT (Table 9). UniNx and EC caused 
cardiac functional changes seen by decreased EF and SV in WT (Table 9). In all other groups, 
no significant differences were observed. 
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Table 8: Functional characteristics of healthy WT and Gas6-/- mice at different age 
  8-12 weeks old, healthy 34-36 weeks old, healthy 
parameter C57BL\6 Gas6-/- C57BL\6 Gas6-/- 
Echocardiography         
         
Left ventricular (LV) mass [mg] 50.82 ± 11.39 73.60 ± 9.72 * 98.55 ± 15.20  80.81 ± 29.50  
Stroke volume (SV) [µl] 23.90 ± 9.05 20.30 ± 6.34 23.61 ± 6.23  19.77 ± 4.3  
Ejection Fraction (EF) [%]  54.33 ± 11.49 45.64 ± 7.76 40.13 ± 9.65  41.50 ± 10.98  
VACC [mm/ms] 2.09 ± 0.98 2.06 ± 1.15 2.13 ± 1.52 1.72 ± 0.72 
(Mean ± SD); * significant to corresponding WT control group 
 
Table 9: Functional characteristics of WT and Gas6-/- mice after different treatments 
Parameter C57BL\6 Gas6-/- 
model Warfarin UniNx Electrocautery Warfarin UniNx Electrocautery 
Echocardiography             
Left ventricular (LV) mass [mg] 79.03 ± 22.00 60.67 ± 14.63  59.10 ± 11.80  69.21 ± 14.74  74.15 ± 28.46   61.36 ± 16.58  
Stroke volume (SV) [µl] 22.00 ± 5.96 13.36 ± 2.68  10.44 ± 2.79  20.55 ± 4.33  24.37 ± 8.90  10.16 ± 6.19 
Ejection Fraction (EF) [%]  46.60 ± 11.55 33.29 ± 13.79  33.75 ± 7.38  44.84 ± 2.66  58.43 ± 21.30* 38.36 ± 17.83 
VACC [mm/ms] 1.97 ± 0.71 2.69 ± 1.01 1.78 ± 0.46 2.26 ± 2.14  3.03 ± 1.38  1.98 ± 0.37 
(Mean ± SD), * significant to corresponding WT control group 
 
 
Chapter 3.3_______________________________________________________________  
 
 90 
3.3.2.5 TUNEL assay  
To test for apoptosis the TUNEL assay was used. In all tested in vivo models (young healthy, 
senescent, warfarin, UniNx, EC), we could not observe different levels of apoptosis in aortas 
between the different groups (data not shown).  
 
3.3.2.6 Collagen staining 
As calcium content in WT mice after warfarin diet was higher only in cardiac tissue, we tested 
for differences in the associated cardiac collagen content by sirius red staining. The size of 
collagen positive areas in cardiac tissues was equal in warfarin treated mice in Gas6-/- and WT 
mice (Figure 50).  
 
 
Figure 50: Collagen staining by sirius red in warfarin treated WT and Gas6-/- mice (50 x). 
 
3.3.2.7 RT-PCR for MGP 
Whether Gas6-/- mice show an upregulation of MGP gene expression in aortic tissues in all 
animal models (young healthy, ageing, warfarin, UniNx, EC) was investigated. However, a 
significant difference in MGP mRNA content in aortic tissue in all experimental groups was 
not detected (Figure 51).  
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Figure 51: MGP gene expression measured by RT-PCR in WT versus Gas6-/- mice. 
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4. DISCUSSION 
Aim 1 was the establishment of an appropriate method for safe and reproducible detection of 
GGCX activity in different tissues. Therefore I developed a fluorescence assay for the 
determination of the activity of the GGCX. This assay determines activities in nanomolar 
range (per gram protein per minute) in microsomes isolated from rat liver, kidney or aorta. 
The assay is based on the synthetically FITC labelled hexapeptide FLEFLK. It contains a 
single carboxylation site and interacts with the active centre of the GGCX enzyme. In vivo γ-
carboxylation is essential for vitamin K dependent proteins. In most of these proteins a 
propetide region with 3 highly conserved amino acids seems to be important for the covalent 
binding with the GGCX enzyme (59). To further identify the interaction of FLEFLK-FITC 
with the GGCX the formation of the enzyme substrate complex could possibly be studied 
using nuclear magnetic resonance spectroscopy (60). The reversed phase-HPLC and MS 
measurements detect both the uncarboxylated as well as the carboxylated peptide as shown by 
the comparison between measured and calculated molecular weights (Table 2). This is 
indicated by different eluted peaks of FLEFLK-FITC and the more hydrophilic FLGLaFLK-
FITC (Figure 18). The shorter retention time of the new appearing peak after in vitro 
carboxylation in rp-HPLC separation suggested a carboxylation of the substrate. This was 
proven by MS fragmentation. The comparison of mass spectrometric fingerprints of rp-HPLC 
eluted probes (Figures 17 and 20) with the calculated molecular weights of the carboxylated 
peptide revealed a high accordance. The additional peaks detected in HPLC (after 18.1 min 
and 18.6 min, Figure 20) may represent degradation products of the original peptide, 
molecular modifications like oxidation or residues from the microsomal matrix. Given the 
expected introduction of a carboxyl-group at the glutamic acid residues of the fragments, 
calculations of corresponding molecular weights are close to measured MW (measured 
fragments 576.7*, 581.5** and 1229.8*** MW, see Table 2 and Figure 20). 
The variation of GGCX activity in liver tissues in the different healthy animals tested was 
quite high. This might be due to different expression levels or alterations of the activity 
caused by unknown conditions requiring further investigations. Age or body weight of the 
animals was similar excluding their influences on the GGCX activity. To our knowledge, 
individual differences in GGCX activity have not been investigated yet. In kidney tissues 
from different animals we found a quite constant enzyme activity.  
The specificity of the assay is underlined by its highly significant inhibition by NEM. NEM is 
an inhibitor of the GGCX (49) by irreversibly alkylating sulfhydryl groups (61). The activity 
in liver tissues was reduced by NEM to 4% and in kidney tissues to 15% of the baseline 
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levels. These data are in line with previously reported results using the conventional 
radioactive carboxylase assay where NEM was found to inhibit the GGCX activity to 5 - 20% 
of baseline levels (49; 50).  
The non-linearity of the substrate variation (i.e. decreased activity at higher concentrations) 
might be caused by an inhibiting effect of acetonitrile of the GGCX activity which is added in 
parallel to the substrate (Figure 26). To compare the efficiency of substrate carboxylation of 
FLEFLK-FITC with the frequently used pentapeptide FLEEL, the kcat/Km value was 
calculated from the slope of the curve of the 14CO2 incorporation assay (Formula 1). Due to 
the inhibiting effect of acetonitrile on the GGCX and the limited solubility of the GGCX in an 
aqueous solution, the substrate concentration could not be further incrased to determine the 
Vmax directly. Based on the slope of the curve  the calculated kcat/KM value that was 3.5 
fold higher  than the one reported for FLEEL (5068 vs. 1413 h-1 mM-1) (58). This increased 
value might indicate a higher turnover of the GGCX in the new assay or a higher affinity for 
substrate FLEFLK-FITC. Nevertheless, the calculated kcat/KM value for FLEFLK-FITC 
indicates a sufficient carboxylation of the substrate. Further investigation on the binding 
between the substrate and the GGCX could explain these results. 
The advantages of the new GGCX assay are the quick and direct measurement of the γ-
carboxylated end product avoiding the hazardous use of radioactive labelled compounds. 
Purification of the substrate is achieved in a one-step procedure after incubation. The HPLC 
measurement yields reliable and reproducible results. This assay seems to be suitable for 
comparative studies between different treatment groups both of in vitro and in vivo 
experiments. It might also be interesting to identify possible GGCX-inhibitors or influences 
of gene mutations on the activity. Also of importance are VKOR/GGCX interactions. One 
reason for an insufficient γ-carboxylation are inhibiting effects on the VKOR as described for 
coumarins (62) but also seen for N-acteyl parabenzoquinone-imine a metabolite of the 
analgetic compound acetaminophen (paracetamol) (63). Determination of GGCX activity 
under several disease conditions might as well be of interest. This protocol is independent of 
the addition of a propeptide, underlining the practical aspect of the new assay. Measuring 
vitamin K dependent carboxylase activity by reversed phase HPLC enables us to calculate the 
activity in nmol/min/g protein, which offers the possibility to directly compare the results 
with the activities of DT-diaphorase and VKOR in one system.  
The combination of the new GGCX assay with the assays to determine VKOR and DT-
diaphorase activities enables one to investigate the complete vitamin K cycle in an in vivo 
model of CKD. For aim 2, the development of a rat model for uremia and vascular 
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calcification in rats, CKD was induced by 0.75% adenine diet. After 4 weeks of adenine diet, 
CKD was present as shown by increased creatinine und urea levels in serum (Table 3). Mild 
increase of the aortic calcium content was present after 4 weeks (Figure 38a) and to a 
calcification was established after 7 weeks of treatment (Figure 38b). The CKD rat model was 
also used to investigate aim 3 - the effect of uremia on the vitamin K cycle and aim 4 - the 
influence of vitamin K supplementation on vitamin K dependent enzyme activities. The 
activities of the enzymes of the vitamin K cycle were measured after 4 and 7 weeks of 
adenine diet. After 4 weeks – when the animals did not exhibit overt calcifications - , vitamin 
K deficiency was already present as evidenced by increased ucMGP serum levels (Figure 31). 
Typically, high serum levels of undercarboxylated proteins such as ucMGP indicate a vitamin 
K deficiency (64;65). At this time point the activity of the GGCX was already reduced at this 
stage of CKD (Figure 32), possibly contributing to the subsequent development of vascular 
calcification found at week 7 (Figure 38). After 4 weeks the VKOR activity was not reduced, 
and the DT-diaphorase was even more active, suggesting that in uremia GGCX is the rate-
limiting enzyme in the vitamin K cycle and a potential major contributor to diminished 
vitamin K availability in tissues.  
In addition, low dietary vitamin K intake has been noted in dialysis patients (7) augmenting 
vitamin K deficiency in uremia. Indeed, dietary vitamin K2 supplementation (100 mg/kg, 
group c) in this present study lowered serum levels of ucMGP (Figure 31). These 
experimental observations parallel those made recently in hemodialysis patients where 
ucMGP serum levels were elevated and could be markedly reduced by dietary vitamin K2 
supplementation (64). Our 4 week CKD model contributes to the understanding of ucMGP 
action in the early stage. Vitamin K treatment resulted in significantly lower calcium tissue 
content in kidneys with a parallel trend in the aorta, strengthening the rationale for the 
planned vitamin K interventional trial VitaVasK targeting cardiovascular calcification in HD 
patients. For aim 5, the influence of oral vitamin K supplementation on vitamin K dependent 
enzyme activites, I assessed in a two-step approach whether correcting vitamin K deficiency 
in this setting rescues the uremic alterations and whether differences exist between treatment 
with vitamin K1 or K2.  
 
To further analyze the influence of vitamin K treatment on tissue calcification, rats were also 
studied after 7 weeks of kidney failure, where overt vascular calcification was established as 
shown in von Kossa stained aortic specimens (Figure 40). The activity of the GGCX was still 
reduced after 7 weeks of adenine in kidney, liver and aortic tissues (Figure 32). High dietary 
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vitamin K2 (500 mg/kg) or K1 (100 mg/kg) restored and even over-stimulated the activity of 
the GGCX in several tissues. In addition, this treatment also significantly reduced 
calcification of the kidneys and heart. In aortic tissue we failed to reach significant differences 
in calcium contents by ANOVA testing which might be due to a high inter-individual 
variability in the extent of aortic calcification in this model. In the heart and kidneys, lower 
dosages of vitamin K1 (100 mg/kg) than vitamin K2 (500 mg/kg) were comparably effective in 
preventing calcification (Figure 38). Although prior observations favour vitamin K2 above K1 
in acting on MGP and vascular calcification (66), our data suggest that vitamin K1 is also 
active in these processes. Another possibility is that vitamin K1 can be converted to K2 inside 
the body as proposed before (67). Why in this study the supplementation of 100 mg/kg 
vitamin K1 was even more potent than 100 mg/kg vitamin K2 in increasing the GGCX activity 
and reducing calcifications needs further investigation. Recently, McCabe found increased 
calcium contents in aortas after adenine diet in rats and successfully reduced vascular 
calcification by dietary vitamin K1 without elucidating the underlying mechanism, i.e. activity 
of the GGCX (68). 
Compared to the daily dietary recommendation for humans (1 µg/kg body weight), the dosage 
of vitamin K supplements was markedly higher in these rat experiments (up to 15 mg/kg body 
weight). Such high dosages were chosen given that there is no evidence of toxicity from even 
very high vitamin K doses in man (69) and based on dosages in prior experimental studies 
(30).  
Unexpectedly, after 7 weeks of adenine treatment, ucMGP levels were on average 16% lower 
than in healthy controls and 41% lower than after 4 weeks of adenine treatment. One 
explanation may be the accumulation of ucMGP in calcified areas in uremia (Figure 40). In 
addition, transdifferentiation of MGP-producing vascular smooth muscle cells into an MGP-
negative osteoblastic phenotype might further reduce ucMGP serum levels as published 
before (70). Our workgroup (unpublished data) and others have observed that MGP-
synthesising VSMC undergo apoptotic processes in calcification (71) which also may lead to 
reduced ucMGP serum levels.  
Because altered GGCX mRNA expression - possibly leading to reduced activity - was not 
detected in all animal groups, the influence of uremic toxins on the low activity of the GGCX 
in CKD was assessed as aim 6. To assess post-transcriptional alterations, I focussed on 
carbamylation of this enzyme by the elevated urea concentrations in CKD. As urea levels rise 
in CKD, it is spontaneously transformed into cyanate which is known to irreversibly 
carbamylate lysine residues. Reversible modifications occur at tyrosine, serine, threonine or 
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cysteine residues, resulting in modification of the activities of enzymes (72). However, in the 
present study in vitro urea concentrations similar to uremic serum levels failed to affect 
GGCX enzyme activity (Figure 34). Two further uremic toxins tested in vitro, p-cresol and 
indoxylsulfate, did not result in altered GGCX activity either. Therefore, the mechanism of 
reduced GGCX activity presently remains unknown.  
To summarize the influence of CKD and vitamin K supplementation on vascular calcification 
I found reduced activity of GGCX in uremia in several tissues possibly contributing to the 
observed functional vitamin K deficiency in dialysis patients. This might represent a key 
contributor to the increased ucMGP levels and excess cardiovascular calcification in CKD in 
rats. Vitamin K1 and vitamin K2 were able to increase GGCX activity and reduce 
extraosseous calcium content in the adenine nephropathy model. Thus, dietary vitamin K 
supplementation in CKD not only reverses the low intake but also rescues endogenous 
vitamin K recycling. By this dual action, the supplementation represents a promising 
therapeutic approach to the massively increased extraosseous calcification in CKD. 
 
For aim 7, clarifying the role of Gas6 protein in vascular calcification I compared mice 
deficient for the protein Gas6 with WT mice. In vitro, VSMC from Gas6 deficient mice were 
challenged with calcification media and in vivo CKD was induced in mice to investigate 
uremic calcification. The main finding of this part of the study is that both in vitro and in vivo 
vascular as well as organ calcification of WT and Gas6-/- mice were not different between 
both genetic backgrounds (Figures 42 and 46).   
Transformation of VSMC into an osteoblastic phenotype is a highly regulated process. 
Among these vitamin K dependent MGP carboxylation (73) and apoptosis (74;75) play a role 
in the calcification process. Previously, Gas6 mRNA stabilisation by statins was found to be a 
protective mechanism in cell culture experiments (21). In these in vitro experiments Gas6 
protected against calcification. However, these findings were only seen in vitro and not 
reproduced in vivo yet.  
Gas6 is also known to mediate antiapoptotic effects (20). In the experiments of this work I did 
not observe increased apoptosis in Gas6-/- mice in vivo and in vitro when compared to WT 
mice. The previous antiapoptotic findings of Gas6 mRNA cannot be confirmed by my results. 
Whether other antiapoptotic compensatory mechanisms are present remains speculative. 
To test for potential other compensatory mechanisms avoiding the development of vascular 
calcification I analysed aortic MGP expression in Gas6-/- mice. MGP is known to be the most 
important local calcification inhibitor in the vessel wall (8) and could act as compensatory 
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mechanism the lack of Gas6. However, MGP was not upregulated in the vessel wall (Figure 
49) indicating that Gas6 deficiency does not influence MGP production.  
Interestingly, I observed a reduced survival of the knockout mice after electrocauterization 
compared to WT (Figure 44). But in mice reaching the designated end point of the treatment 
period, no augmented calcification was observed. As the mice died close to surgical 
procedures, calcification processes appear unlikely to be the reason for the increased 
mortality. One might speculate that inflammatory processes may play a role. Gas6 secretion is 
stimulated by TGF-ß (76) and Gas6 expressesion in atherosclerotic plaques was inversely 
associated with inflammation (76). In these experiments neither signs of inflammation in the 
vessel wall nor accumulation of collagen were observed. Other potential reasons could play a 
role for the decreased survival rate e.g. the lower body weight of the knockout animals. 
Alternatively, Gas6 knockout mice were reported to be protected from arterial thrombosis 
(77). Thus, it could be speculated that altered coagulation of the uremic Gas6-/- mice 
contributed to increased mortality. However, as we could not find tissue infarction or signs of 
bleeding, this mechanism does not seem to be responsible for the death rate of the Gas6-/- 
mice. 
Interestingly, Gas6-/- mice had a higher left ventricular mass as assessed by heart ultrasound 
despite a smaller body weight (Table 6). This was accompanied with a lower, non significant 
reduction in ejection fraction (Table 8). Strikingly, calcium content of the myocardium was 
significantly lower in Gas6-/- mice compared to WT after warfarin diet (Figure 46). The 
reasons for this phenomenon remain speculative but one should consider that the detected 
cardiac calcium content ranging at 0.1 mg/g is very low and does not resemble overt 
calcification. Cardiac calcification is also associated with fibrosis (78) and cardiac fibroblast 
growth was found to be stimulated by Gas6 (19). Therefore we speculated that protective 
effects of lacking Gas6 might depend on a different collagen content of the hearts. Also, Gas6 
was found to inhibit mRNA expression of collagen II (79). However, in our study collagen 
staining was equal in both Gas6-/- and WT mice.  
 
One drawback of this part of the study is the use of the calcification resistant C57BL/6 genetic 
background of the mice in contrast to DBA/2 mice which are more prone to calcification (80). 
Mice deficient for Fetuin A on a C57BL/6 background (B6,129-Ahsgtm1Mbl) develop only 
minor ectopic microcalcifications in soft tissues (81). Fetuin A deficient mice backcrossed 
onto the DBA/2 background exhibit more severe calcification of different tissues (82). 
Nevertheless, in all of our models early calcification spots could be induced on the C57BL/6 
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background and the lack of aggravated calcification by depletion of Gas6 does not support a 
major role of Gas6 in vascular calcification pathogenesis.  
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5 CONCLUSIONS 
 
The importance of vitamin K besides blood coagulation is a topic of current interest. All 
vitamin K dependent blood coagulation factors contain 9-12 Glu residues. Calcium binding is 
the crucial mechanism of all vitamin K dependent proteins. In their carboxylated form, Gla 
residues are capable to bind to phospholipid layers coupled with calcium ions. Vitamin K is 
regarded to prevent calcification of soft tissues by carboxylating MGP and the calcium 
binding property gained by this procedure is regarded as the main reason of MGP acting as a 
calcification inhibitor. A functional vitamin K deficiency is found in dialysis patients as 
shown by increased serum levels of ucMGP, ucOcn and PIVKAII. These patients exert 
pronounced vascular calcification which contributes to a highly increased mortality and 
morbidity. The reduced vitamin K deficiency under uremia is the topic of this work. Here I 
demonstrated that under uremic conditions the activity of the key enzyme of the vitamin K 
cycle γ-glutamyl carboxylase is reduced and can be reversed by high dose vitamin K 
supplementation whereas the remaining enzymes were unaffected by uremia. Further research 
will be needed to investigate the mechanism underlying the reduced GGCX activity in kidney 
disease. Vitamin K supplementation was able to reduce the extent of soft tissue calcification 
in rats with kidney failure. This was paralleled by an increase of the activity of the GGCX and 
a reduction of ucMGP serum levels. This suggests that increasing the amount of dietary 
vitamin K offers a therapeutic target to prevent calcification processes in patients with kidney 
disease. Not only for vitamin K deficient patients like kidney patients but also for healthy 
people a higher daily, dietary vitamin K recommendation should be taken under 
consideration. But special care might be taken in diabetic patients, because the carboxylated 
form of osteocalcin is associated with decreasing insulin sensitivity although data on a direct 
harmful effect is lacking.  
Some studies suggest a role of the vitamin K dependent protein Gas6 in preventing vascular 
calcification. Here I did not detect any effects of Gas6 deficiency on the development of 
vascular calcification in mice. 
Human interventional trials are still needed to clarify the efficacy of vitamin K treatment. Of 
interest are also potential beneficial effects of high vitamin K intake in healthy individuals as 
well as differences of vitamin K subforms on metabolic and clinical effects.  
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